
5. CLINICAL MICROBIOLOGY:

5.1. Diagnosis of *Cryptosporidium parvum* infection:

Diagnosis of *Cryptosporidium* is based on identification of oocyst(s) in stool samples. There is no consensus on the number of stool samples that should be tested to confirm absence of the parasite since shedding of oocysts in the fecal samples is intermittent. However, examination of three or more stool samples within 5 days of initiation of therapy is generally recommended for drug efficacy testing^{13,14}. In cases where the oocyst counts are low, concentration of stool samples was shown to improve the detection of oocysts. Several staining methods are available for detection of oocysts in stool samples such as iodine staining, acid fast staining, auramine-rhodamine staining, auramine-phenol staining, Giemsa's staining, and acridine orange staining. However, acid fast staining is the most sensitive of the staining methods and is routinely used for diagnosis. Although acid fast staining of stool sample is easy to perform and cost effective, variation in staining with age of oocysts has been observed and identification is dependent on the skills of the laboratory technician. The acid fast staining technique does not detect ghost oocysts (oocysts that have shed the sporozoites), although patients with ghost oocysts continue to have the infection.

Besides staining, other assays such as immunofluorescence and enzyme linked immunoassays are available for the detection of oocysts. These methods are more sensitive than the staining methods for diagnosis of *C. parvum* infection, however, they require specialized equipment. The advantage of the immunofluorescence method is that it can detect ghost oocysts.

Concentration of stool samples in combination with more sensitive identification techniques and quantitative expression of results using multiple stool samples may be useful in enumeration of oocyst(s). Examination of stool samples detects the oocyst stage of the parasite. The other stages of the parasite are intracellular and would require examination of tissue biopsy samples.

5.2. Clinical studies:

Three phase III randomized, double blind, placebo controlled studies (RM-NTZ-98-002, RM02-3007, and RM02-3008) were conducted to examine the safety and efficacy of nitazoxanide (100 mg, 200 mg or 500 mg, administered orally twice daily for 3 days with food) in the treatment of cryptosporidial diarrhea in adults and children. Subjects with diarrhea (defined as ≥ 3 bowels/day) with or without other symptoms (i.e., tenesmus, loose stools, bloody stools, rectal bleeding or enlarged colon) and a positive diagnosis for *C. parvum* oocysts in stool samples collected 1 to 7 days prior to initiation of therapy were enrolled. HIV positive subjects were excluded. In addition, patients receiving other antiparasitic/antihelminthic therapies and/or those with hypersensitivities to nitazoxanide or nitroimidazoles were excluded.

In study RM-NTZ-98002, 50 adults (≥ 12 years) and 50 children (<12 years) from Egypt with cryptosporidial diarrhea and associated protozoan and helminthic infections were enrolled. The diagnosis of *C. parvum* was based on microscopic examination of a drop of fecal sample after staining with the Ziehl-Neelson acid-fast stain (ZNN; 1000X magnification). Concentrated stool samples were not examined. In some cases the direct immunofluorescence assay (IFA) using the

Cryptaz

Romark Laboratories

_____ kit (manufactured by _____ approved by FDA for diagnosis of *C. parvum*) was used in addition to ZNN. Although the protocol stated that patients should have a positive *C. parvum* diagnosis 7 days prior to start of therapy, in 20 patients diagnosis was made 8 to 19 days prior to enrollment. The protocol also called for detection of *C. parvum* in stool samples by PCR, however, the sponsor has stated that the assay was not performed because it could not be standardized. The diagnostic methods used for identification of other protozoa/helminths/bacteria are shown in Table 22. HIV infections were diagnosed using the _____ Rapid Test.

Table 22: Diagnostic methods for detection of protozoa/helminths/bacteria

Protozoa/Helminth/Bacteria	Diagnostic method
<i>Entamoeba coli</i>	Microscopic examination of stool
<i>Entamoeba histolytica</i>	Microscopic examination of stool, PCR-SHELA technique
<i>Giardia lamblia</i>	Microscopic examination of stool
<i>Endolimax nana</i>	Microscopic examination of stool
<i>Iodamoeba butschii</i>	Microscopic examination of stool
<i>Dientamoeba fragilis</i>	Microscopic examination of stool
<i>Isospora belli</i>	Microscopic examination of stool
<i>Blastocystis hominis</i>	Microscopic examination of stool
<i>Cyclospora cayatanensis</i>	Microscopic examination of stool
<i>Balantidium coli</i>	Microscopic examination of stool
<i>Enterobius vermicularis</i>	Microscopic examination of stool, Graham scotch test
<i>Ascaris lumbricoides</i>	Microscopic examination of stool, Egg count by Kato-Katz kit
<i>Necator americanus</i>	Microscopic examination of stool, Egg count by Kato-Katz kit
<i>Ancylostoma duodenale</i>	Microscopic examination of stool, Egg count by Kato-Katz kit, coproculture using Harada/Mori technique
<i>Trichuris trichura</i>	Microscopic examination of stool Egg count by Kato-Katz kit
<i>Strongyloides stercoralis</i>	Microscopic examination of stool Baermann concentration tests
<i>Taenia saginata</i>	Microscopic examination of stool
<i>Taenia solium</i>	Microscopic examination of stool
<i>Hymenolepis nana</i>	Microscopic examination of stool, Egg count by Kato-Katz kit
<i>Fasciola hepatica</i>	Microscopic examination of stool
<i>Heterophyes heterophyes</i>	Microscopic examination of stool
Salmonella	Culture
Shigella	Culture

The primary endpoints of the study were (a) resolution of clinical symptoms, and (b) absence of *C. parvum* oocysts in two stool samples collected 24 hours apart between days 5 and 12 of initiation of treatment. Please note that although the protocol defined endpoint was parasitological cure between days 5 and 12, the parasitological evaluations were performed between days 6 and 23. The clinical response was defined as “well” if at the time of clinical evaluation (day 7 ± 2 after initiation of treatment) the patient had (a) no symptoms, no watery stools or ≤ 2 soft stools and no hematochezia within the past 24 hours, or (b) no symptoms and no unformed stools within the past 48 hours. The secondary endpoint was absence of cyst/trophozoites/eggs/larvae of other protozoa or helminths in two stool samples obtained between days 5 and 12 of initiation of treatment. For efficacy analysis, patients with mixed infections (*C. parvum* + other protozoa/helminths) at baseline were excluded.

Cryptaz
Romark Laboratories

The results of the parasitological and clinical efficacy of nitazoxanide and placebo in the treatment of different patient populations which includes children (ages 1-3 and 4-11 years) and adults (≥ 12 years) with cryptosporidial diarrhea are shown in Tables 23 to 26 and summarized in Table 27. The detection of oocysts by the IFA test appears to be better than that of ZNN staining based on a small number of patients (2 each in the placebo and NTZ arm; Table 23). The use of two different methods appears to improve the detection of oocyst.

Subjects positive for oocysts in one post-treatment stool sample and negative in another stool sample were observed in both placebo (8/50; 16%) and nitazoxanide treatment (7/50; 14%) groups (Tables 23 to 26) thereby suggesting that examination of two or more post-treatment stool samples is helpful for evaluation of drug efficacy.

Of the 7 children under the age of 3 with cryptosporidial diarrhea, 4 (57%) children showed absence of oocysts in stool samples within 6 to 16 days of initiation of therapy with nitazoxanide (100 mg b.i.d. for 3 days, see Tables 23 and 27) and diarrhea was resolved in 3 of the 4 patients. The remaining 3 (43%) children were clinically well but continued to shed oocysts. Placebo was less effective than nitazoxanide and eradicated oocysts in 2/9 (22%) children and one of the 2 patients resolved diarrhea (Tables 23 and 27). In addition, one patient in the placebo group was clinically well but continued to shed oocysts. The remaining 6 patients continued to have diarrhea and shed oocysts. The time of evaluation of clinical response in these patients was not specified. Based on the information on the small number of patients there appears to be a lack of correlation between parasitological and clinical responses.

In older children (ages of 4-11 years) with cryptosporidial diarrhea, nitazoxanide (200 mg b.i.d. for 3 days) was effective in eradicating oocysts within 6 to 16 days of initiation of therapy in 7/8 (88%) patients (Tables 24 and 27). All of the 7 children were clinically well. One patient failed therapy both clinically and parasitologically. In children treated with placebo, however, 2/12 (17%) showed absence of oocysts in the post-treatment stool samples and both of them continued to have diarrhea (Tables 24 and 27). Four children (36C, 39C, 31C, and 19C) in the placebo arm although clinically well continued to shed oocysts in the stool. The remaining 6 subjects continued to have diarrhea and shed oocysts in stool. The time of evaluation of clinical response was not specified. There appears to be a correlation between parasitological and clinical outcomes in a small number of children treated with nitazoxanide.

In adults (≥ 12 years) treated with nitazoxanide (500 mg b.i.d. for 3 days), eradication of oocysts was observed in stool samples in 12/21 (57%) patients and resolution of diarrhea in 7 of the 12 patients (Tables 26 and 27). One patient failed therapy both clinically and parasitologically. Placebo treatment eradicated oocysts in 6/21 (28%) patients, and 3 of the 6 patients resolved diarrhea (Tables 25 and 27). Nine patients continued to have diarrhea and shed oocysts. Six out of 21 patients in the placebo arm and 8/21 in the nitazoxanide arm resolved diarrhea but continued to shed oocysts. The time of evaluation of clinical response for these patients was not specified. There appears to be a lack of correlation between parasitological and clinical responses in adults treated with nitazoxanide.

Table 23: Parasitological and clinical responses in children under the age of 3 years with cryptosporidial diarrhea after treatment with nitazoxanide or placebo for 3 days.

Age in Years (Treatment Group)	Patient ID	Oocysts at baseline stool sample ZNN (IFA)	Oocysts in stool samples on different days after initiation of therapy ZNN (IFA)													Parasitologic response	Clinical response	
			6	7	8	9	10	11	12	13	14	16						
1-3 years (Placebo b.i.d 3 days)	3C ^{bd}	0-1 (+)	- (-)														Eradicated	Well
	4C ^b	0-2 (+)	- (-)														Eradicated	CI
	5C ^l	+ (30-40)	0-1 (3-10)														Failed	CI
	6C	+ (30-40)	0-2 (5-15)														Failed	CI
	26C	1-2 (ND)															Failed	CI
	17C ^{a*}	1-3 (ND)															Failed	Well
	22C	1-3 (ND)		1-4 (ND)					1-3 (ND)								Failed	CI
	27C	2-4 (ND)							1-3 (ND)		8-10 (ND)						Failed	CI
	41C ^d	2-4 (ND)							1-3 (ND)								Failed	CI
	50C	3-5 (ND)		4-7 (ND)					8-12 (ND)								Failed	Well
1-3 years (NTZ 100 mg b.i.d 3 days)	11C ^{a*}	3-5 (ND)															Eradicated	Well
	28C ^{a,b,h}	0-2 (ND)															Eradicated	Well
	2C ^f	0-3 (+)	0-1 (5-25)														Failed	Well
	9C ^b	0-3 (0-3)	- (-)														Eradicated	Well
	44C ^b	0-3 (ND)	- (ND)														Failed	Well
	30C ^b	1-3 (ND)															Eradicated	Well
	43C	1-3 (ND)															Eradicated	Well
	7C ^b	3-5 (10-20)	+ (0-1)														Failed	Well
	28C ^{a,b,c}	3-5 (ND)															Eradicated	Well
	42C	4-6 (ND)															Eradicated	CI
34C ^{a*}	5-7 (ND)															Eradicated	Well	
21C ^{a*}	6-8 (ND)															Failed	NA	
1C ^{a*}	2-10 (+)															Eradicated	Well	

* excluded (shaded cells)
 ** did not take medication and excluded
 NTZ = nitazoxanide
 ZNN = Ziehl-Neelson acid fast staining
 IFA = immunofluorescence assay
 CI = Continuing illness
 + = positive result

^a *Entamoeba histolytica* cyst/trophs at baseline
^b *Blastocystis hominis* at baseline
^c *Giardia lamblia* at baseline
^d *Enterobius vermicularis* at baseline
^e *Hymenolepis nana* at baseline
^f *Taenia* spp
 - = negative result

^a *Entamoeba histolytica* cyst/trophs at post-treatment
^b *Blastocystis hominis* at post-treatment
^c *Giardia lamblia* at post-treatment
^d *Enterobius vermicularis* at post-treatment
^e *Hymenolepis nana* at post-treatment
 NA = Not available
 ND = Not done

Table 24. Parasitological and clinical responses in children (4-11 years) with cryptosporidial diarrhea after treatment with nitazoxanide or placebo for 3 days.

Age in Years (Treatment Group)	Patient ID	Oocysts at baseline stool sample ZNN (IFA)	Oocysts in stool samples on different days after initiation of therapy ZNN (IFA)										Parasitologic response	Clinical response			
			6	7	8	9	10	12	13	14	15	16					
4-11 years	14C ^e	1-3 (ND)	1-3 (ND)												Failed	CI	
	32C	1-3 (ND)												1-3 (ND)	1-3 (ND)	Failed	CI
	15C ^{a,b}	3-5 (ND)	1-2 (ND)						0-2 (ND)							Failed	well
	16C	3-5 (ND)														Failed	CI
	20C ^e	3-5 (ND)														Eradicated	CI
	36C	3-5 (ND)														Failed	well
	23C ^d	4-6 (ND)														Failed	CI
	39C ^d	4-7 (ND)														Failed	well
	31C	5-7 (ND)														Failed	well
	46C ^e	5-7 (ND)														Eradicated	CI
4-11 years	33C ^{a,b}	6-8 (ND)														Failed	CI
	19C	5-11 (ND)														Failed	well
	48C	7-10 (ND)														Failed	CI
	40C	8-10 (ND)														Failed	CI
	8C	0-1 (-)														Eradicated	well
	10C	1-2 (ND)														Eradicated	well
	37C ^b	1-2 (ND)														Eradicated	well
	38C ^{a,b}	1-3 (ND)														Eradicated	well
	45C ^{a,b}	1-3 (ND)														Failed	CI
	12C ^a	2-4 (ND)														Eradicated	well
29C	2-4 (ND)														Eradicated	well	
18C	3-5 (ND)														Eradicated	well	
24C ^{a,b}	3-5 (ND)														Eradicated	well	
13C	4-6 (ND)														Failed	CI	
49C	4-6 (ND)														Eradicated	well	
47C ^{a,b}	4-7 (ND)														Failed	well	
35C	5-7 (ND)														Eradicated	well	

* excluded (shaded cells)
 NTZ = nitazoxanide
 ZNN = Ziehl-Neelson acid fast staining
 IFA = immunofluorescence assay
 + = positive result

^a *Entamoeba histolytica* cyst/trophs at baseline
^b *Blastocystis hominis* at baseline
^c *Giardia lamblia* at baseline
 CI = Continuing illness
 - = negative result

^d *Blastocystis hominis* at post-treatment
^e *Giardia lamblia* at post-treatment
^f *Enterobius vermicularis* at post-treatment
 ND = Not done

Table 25: Parasitological and clinical responses in adults (≥ 12 years) with cryptosporidial diarrhoea after treatment with placebo for 3 days.

Patient ID	Oocysts at baseline stool sample ZNN (IFA)	Oocysts in stool samples on different days after initiation of therapy ZNN (IFA)											Parasitologic response	Clinical response			
		6	7	8	9	10	11	12	13	14	17	23					
31A	0-2 (ND)															Failed	well
16A	0-2 (ND)	- (ND)	1-3 (ND)		3-5 (ND)	2-5 (ND)										Failed	CI
28A	0-3 (ND)	0-3 (ND)			0-2 (ND)											Failed	well
7A	1-2 (ND)	- (ND)										- (ND)				Failed	CI
17A	1-2 (ND)	- (ND)														Eradicated	CI
39A	1-2 (ND)				4-6 (ND)					7-9 (ND)						Failed	CI
43A	1-2 (ND)				1-3 (ND)											Failed	CI
48A	1-2 (ND)				3-5 (ND)											Failed	CI
5A	1-3 (ND)															Eradicated	CI
25A	1-3 (ND)	- (ND)									1-2 (ND)					Failed	well
27A	1-3 (ND)				4-6 (ND)											Failed	CI
40A	1-3 (ND)	4-7 (ND)								5-7 (ND)						Failed	well
42A ^a	1-3 (ND)		2-4 (ND)		2-4 (ND)	5-7 (ND)										Failed	well
44A ^b	1-3 (ND)				2-4 (ND)											Failed	well
45A ^{a,c,d}	1-3 (ND)		3-5 (ND)		1-3 (ND)							6-9 (ND)				Failed	CI
23A ^{a,c,d}	2-4 (ND)				1-3 (ND)											Failed	CI
33A ^d	2-4 (ND)				0-2 (ND)											Failed	well
11A	3-5 (ND)				- (ND)							- (ND)				Eradicated	well
13A	3-5 (ND)				- (ND)											Eradicated	well
4A	3-6 (ND)				4-6 (ND)											Failed	CI
29A ^b	4-6 (ND)				1-2 (ND)				0-2 (ND)							Failed	CI
38A	8-12 (ND)								1-3 (ND)							Failed	CI
21A	10-15 (ND)				- (ND)											Failed	CI
36A ^e	10-15 (ND)								- (ND)							Eradicated	well

* excluded (shaded cells)
 NTZ = nitazoxanide
 ZNN = Ziehl-Neelson acid fast staining
 CI = Continuing illness
 + = positive result

^a *Entamoeba histolytica* cysts/trophs at baseline
^b *Entamoeba histolytica* cysts/trophs at post-treatment
^c *Giardia lamblia* at baseline
^d *Giardia lamblia* at post-treatment
^e *Hymenolepis nana* at post-treatment

IFA = immunofluorescence assay
 ND = Not done
 - = negative result

Table 26: Parasitological and clinical responses in adults (≥ 12 years) with cryptosporidial diarrhea after treatment with nitazoxanide (500 mg b.i.d) for 3 days.

Patient ID	Oocysts at baseline stool sample ZNN (IFA)	Oocysts in stool samples on different days after initiation of therapy ZNN (IFA)										Parasitologic response	Clinical response			
		6	7	8	9	10	11	12	13	15	16					
1A	0-1 (ND)	- (-)		- (-)											Eradicated	well
2A ^{a*}	0-1 (ND)	0-2 (ND)		0-2 (ND)											Eradicated	well
19A	0-1 (ND)	- (ND)		- (ND)											Failed	well
32A ^d	0-2 (ND)	- (ND)		- (ND)											Eradicated	well
26A	0-2 (ND)	- (ND)		- (ND)											Eradicated	CI
47A ^d	0-2 (ND)	- (ND)		- (ND)											Eradicated	CI
50A	0-2 (ND)	- (ND)		- (ND)											Eradicated	CI
14A ^{a,b*}	1-3 (ND)	- (ND)		- (ND)											Eradicated	well
18A	1-3 (ND)	3-5 (ND)		2-4 (ND)											Failed	CI
22A	1-3 (ND)	2-4 (ND)													Failed	well
34A	1-3 (ND)	- (ND)		2-4 (ND)											Failed	well
49A	1-3 (ND)	- (ND)		- (ND)											Eradicated	CI
6A	2-4 (ND)	- (ND)		- (ND)											Eradicated	well
10A	2-4 (ND)	- (ND)		- (ND)											Eradicated	CI
20A	2-4 (ND)	1-2 (ND)													Failed	well
41A	2-4 (ND)	- (ND)		- (ND)											Eradicated	well
46A	2-4 (ND)	- (ND)		- (ND)											Eradicated	well
8A ^{a,c,d}	3-5 (ND)	0-2 (ND)		1-2 (ND)											Failed	well
9A	3-5 (ND)	- (ND)		- (ND)											Eradicated	well
24A	3-5 (ND)	- (ND)		- (ND)											Failed	well
2A ^{a,b*}	5-7 (ND)	- (ND)		- (ND)											Eradicated	CI
37A	5-7 (ND)	- (ND)		- (ND)											Eradicated	well
13A	6-8 (ND)	- (ND)		2-4 (ND)											Failed	well
3A	8-15 (ND)	- (ND)		- (ND)											Failed	well
30A	10-12 (ND)	3-5 (ND)		- (ND)											Failed	well

* excluded (shaded cells)

NTZ = nitazoxanide

ZNN = Ziehl-Neelson acid fast staining

IFA = immunofluorescence assay

+ = positive result

ND = Not done

^a *Entamoeba histolytica* cyst/trophs at baseline

^b *Entamoeba histolytica* cyst/trophs at post-treatment

^c *Giardia lamblia* at baseline

^d *Giardia lamblia* at post-treatment

CI = Continuing illness

- = negative result

Cryptaz
Romark LaboratoriesTable 27: Summary of the efficacy of nitazoxanide in immunocompetent patients with *C. parvum* infection (RMNTZ 98-002).

Treatment group	Age in years	baseline parasite counts using ZNN (no of subjects)	No. of patient		Parasitologic and clinical responses		patients with eradication of oocysts N (%)	Clinical well response N (%)	patients clinical well and eradicated oocysts N (%)
			total	excluded	Eradicated (CR)	Persisted (CR)			
Placebo b.i.d 3 days	1-3	1-5	11	2	1 (well); 1 (CI)	1 (well); 6 (CI)	2 (22)	2 (22)	1 (11)
	4-11	≤ 3 (2)	14	2	2 (CI)	4 (well); 6 (CI)	2 (17)	4 (33)	0 (0)
		>3 <10 (11) >10 (1)							
≥ 12	≤ 3 (16) >3 <10 (6) >10 (3)	25	4	3 (well); 3 (CI)	6 (well); 9 (CI)	6 (28)	9 (43)	3 (14)	
NTZ 100 mg b.i.d 3 days	1-3	≤ 3 (6) 12 >3 <10 (6)		5	3 (well); 1 (CI)	3 (well)	4 (57)	6 (86)	3 (43)
NTZ 200 mg b.i.d 3 days	4-11	≤ 3 (5) 13 >3 <10 (8)		5	7 (well)	1 (CI)	7 (88)	7 (88)	7 (88)
NTZ 500 mg b.i.d 3 days	≥ 12	≤ 3 (12) >3 <10 (11) >10 (2)	25	4	7 (well); 5 (CI)	8 (well); 1 (CI)	12 (57)	15 (71)	7 (33)

NTZ = Nitazoxanide;
CI = continuing illness;
CR = clinical response;
N = number of subjects.

In summary, examination of ≥ 2 stool samples is helpful for determination of parasitological efficacy of the drug. Evaluation of stool samples by two different methods improved the detection of oocysts in stool samples. A total of 23 out of 36 (64%) patients eradicated the oocysts within 6 to 23 days after initiation of therapy with nitazoxanide (100 mg, 200 mg, or 500 mg) compared to 10/42 (24%) patients in the placebo arm. There appears to be a lack of correlation between the parasitological and clinical outcomes in patients with cryptosporidial diarrhea treated with nitazoxanide except in children 4-11 years of age (Table 27).

In study RM02-3007, 50 HIV negative children (≤ 3 years old) with cryptosporidial diarrhea from Zambia were enrolled. The inclusion/exclusion criteria were same as study RM-NTZ-98-002 except that only subjects with *C. parvum* oocysts in 2 stool samples collected at the time of screening (7-10 days prior to enrollment) and at baseline were enrolled. Exclusion of subjects with *Entamoeba histolytica* and *Giardia lamblia* infections was based on a positive test using a FDA approved enzyme immuno-assay kit. The HIV infections were

Cryptaz
Romark Laboratories

diagnosed using the Rapid test. Only subjects who were HIV negative were enrolled. Subjects were treated with nitazoxanide (100 mg b.i.d) for 3 days.

The primary endpoint of this study was resolution of clinical symptoms. The secondary endpoints were (a) absence of *C. parvum* oocysts in two stool samples collected 24 hours apart between days 7 and 15 after initiation of therapy, and (b) time to passage of last unformed stool. Microscopic examination of unconcentrated and/or concentrated stool samples stained with auramine-phenol was used to identify *C. parvum* oocysts. The sponsor has stated that concentrated stool samples were processed for the presence of oocysts only if the unconcentrated stool samples were negative for oocysts. However, it appears that this criterion was not used uniformly. No other method was used for detection of oocysts. In 3 patients, the diagnosis of *C. parvum* infection at screening was made using the enzyme immunoassay kit () only. It should be noted that the test consists of antibodies to the *G. lamblia* alpha-1-giardin, *E. histolytica* 29 kDa surface protein and *C. parvum* protein disulfide isomerase and has been approved for diagnosis of *C. parvum*, *G. lamblia* and *E. histolytica* infections. The test can be performed only using fresh stool sample within 72 hours of collection.

One of the patients (#10) had infection due to *G. lamblia* and was excluded from the efficacy analysis (Table 28).

Discordance in the test results of the 2 stool samples collected at post-treatment was observed in some of the patients (Table 28). In the placebo and nitazoxanide treatment groups, 35% (6/17) and 8% (2/24) patients, respectively, were positive for oocysts in one stool sample and negative in the other stool sample. This could be due to intermittent shedding of oocysts. Examination of two or more post-treatment samples appears to be necessary for evaluation of drug efficacy.

Eradication of oocysts was observed in the stool samples from 3/25 (12%) patients collected between days 7 and 11 in the placebo group. Of the 3 patients, one was clinically well (Tables 28 and 29). Three patients (# 32, 34 and 46) in the placebo arm were positive for *C. parvum* oocysts at screening but were negative on the day of initiation of treatment. The clinical outcome of these patients was not described. The sponsor has excluded these patients from efficacy analysis. However, for the purpose of this review these patients were included in the analysis so that comparison can be made across different studies using the same inclusion criteria i.e., presence of oocysts 7 to 10 days prior to enrollment. Diarrhea and shedding of oocysts was observed in 10/25 (40%) patients. Five patients were lost to follow-up. Oocysts were absent in post-treatment stool samples (collected between days 7 and 15) from 12/24 (50%) patients treated with nitazoxanide (Tables 28 and 29). Of these, 7 patients were clinically well. Six patients failed therapy both clinically and parasitologically. Four patients in the placebo group and six in the nitazoxanide group were clinically well but continued to shed oocysts. The time of evaluation of the clinical response was not specified. There appears to be no correlation between the clinical and parasitological outcomes in these children.

Cryptaz
Romark Laboratories

Table 28: Parasitological and clinical efficacy of Zambian children with *C. parvum* infection in the placebo and nitazoxanide treatment groups (treatment administered for 3 days).

Group	Patient ID	Oocysts at baseline stool sample UC (C)	Oocysts in stool samples on different days after initiation of therapy UC (C)						Parasitologic response	Clinical response		
			7	8	9	10	11	13			15	
Placebo b.i.d 3 days n = 25	2	+(ND)	+(ND)				-(0)				well	
	4	+(ND)		-(0)	-(0)					Eradicated	well	
	6	+(ND)									CI	
	9	+(ND)								Lost to follow up		
	16	+(ND)								Lost to follow up		
	26	+(ND)								Lost to follow up		
	7	+(1+)		+(ND)				-(0)			CI	
	12	+(1+)		-(0)				+(ND)			well	
	24	+(1+)		-(0)	-(ND)					Eradicated	CI	
	27	+(1+)		-(0)	-(ND)					Eradicated	CI	
	37	+(1+)								Lost to follow up		
	39	+(1+)		+(1+)	+(1+)						CI	
	47	+(1+)		+(2+)	+(2+)						CI	
	49	+(1+)		+(1+)	-(0)						well	
	14	+(2+)		+(3+)	+(1+)						CI	
	17	+(2+)		+(ND)		-(0)					CI	
	29	+(2+)		+(1+)	+(1+)						CI	
	42	+(2+)		+(1+)	-(0)						CI	
	44	+(2+)								Lost to follow up		
	22	+(3+)		+(2+)	+(3+)						CI	
36	+(3+)		+(3+)	+(2+)						CI		
19	+(4+)		+(1+)	-(0)						well		
32**	-								Eradicated	NA		
34**	-								Eradicated	NA		
46**	-								Eradicated	NA		
NTZ 100 mg b.i.d 3 days n = 24	1	+(ND)		-(0)					-(0)		Eradicated	CI
	3	+(ND)		-(0)			-(0)				Eradicated	well
	5	+(ND)		+(ND)								CI
	8	+(ND)		-(0)					-(0)		Eradicated	CI
	15	+(ND)		-(0)	-(0)						Eradicated	well
	11	+(1+)		+(1+)	+(1+)							CI
	13	+(1+)		+(1+)	+(1+)							CI
	23	+(1+)		-(0)	-(0)						Eradicated	CI
	25	+(1+)	+(+1)	+(+1)								well
	28	+(1+)		-(0)	-(0)						Eradicated	well
	31	+(1+)	-(0)	-(0)							Eradicated	CI
	38	+(1+)		+(1+)	-(0)							well
	41	+(1+)		-(0)	-(0)						Eradicated	CI
	45	+(1+)		-(0)	-(0)						Eradicated	well
	48	+(1+)		+(1+)	+(1+)							CI
	50	+(1+)			-(0)	+(1+)						well
	21	+(2+)	+(+1)		+(1+)							well
	35	+(2+)		-(0)	-(0)						Eradicated	well
	40	+(2+)			-(0)				-(0)		Eradicated	well
	43	+(2+)	-(0)	-(0)							Eradicated	well
18	+(3+)		+(1+)	+(2+)							well	
30	+(3+)		+(1+)	+(1+)							CI	
33	+(3+)		+(1+)	+(1+)							CI	
20	+(4+)		+(3+)	+(4+)							well	
10*	+(ND)		-(0)	-(0)						Eradicated	well	

NTZ = Nitazoxanide; UC = unconcentrated stool; C = concentrated stool; + = positive result;
 - = negative result; ND = Not done; CI = continuing illness; NA = not available

*excluded due to mixed infection with *Giardia* (shaded cell)

** positive for oocysts at screening (7-10 days prior to start of therapy) and negative at baseline;

0 = no oocyst entire smear;

2+ = <5 oocyst per microscopic field (100X magnification);

4+ = 11-20 oocyst per microscopic field (100X magnification);

1+ = <5 oocyst per microscopic field (100X magnification);

3+ = 5-10 oocyst per microscopic field (100X magnification);

5+ = >20 oocyst per microscopic field (100X magnification).

Cryptaz
Romark Laboratories

Table 29: Summary of parasitological and clinical responses of immunocompetent children with *C. parvum* infection (RM02-3007).

Treatment group	Age in years	Baseline parasite score (no of subjects)	No. of patient		Parasitologic and clinical response		Patients with eradication of oocysts N (%)	Patients with Clinical well response N (%)	Patients clinical well and eradicated oocysts N (%)
			total	excluded	Eradicated (CR)	Persisted (CR)			
Placebo* b.i.d 3 days	1-3	≤ 2+ (22) ≤ 4+ (3)	25	0	1 (well); 2 (CI); 3 (NA)	4 (well); 10 (CI)	6 (24)	5 (20)	1 (4)
100 mg NTZ b.i.d 3 days	1-3	≤ 2+ (21) ≤ 4+ (4)	25	1	7 (well); 5 (CI)	6 (well); 6 (CI)	12 (50)	13 (54)	7 (29)

NTZ = Nitazoxanide

NA = clinical response not available

* 5 patients lost to follow-up

CR = clinical response;

N = number of subjects

Parasite score: 0 = no oocyst entire smear;

2+ = <5 per microscopic field (100X magnification)

3+ = 5-10 per microscopic field (100X magnification)

4+ = 11-20 per microscopic field (100X magnification)

Some of the patients who continued to shed oocysts or were clinically ill after treatment with the placebo or nitazoxanide were treated with nitazoxanide (100 mg bid for 3 days) in an open-label protocol (Table 30). Two patients previously treated with placebo (#2 and #27) and one patient (#1) previously treated with nitazoxanide had parasitological evaluations based on one stool sample and were excluded from analysis. The results in Table 30 show that eradication of oocyst and resolution of diarrhea was observed in 6 patients (1/7 patients with prior placebo treatment and 5/12 patients with prior nitazoxanide treatment). In addition, the results also support the fact that detection of oocysts in < 2 samples may be insufficient for measuring parasitological outcome after treatment with an anti-cryptosporidial drug

In summary, 7/24 (29%) children (≤ 3 years) showed a parasitological and clinical cure after treatment with nitazoxanide (100 mg b.i.d for 3 days) compared to 1/25 (4%) in the placebo arm.

Cryptaz
Romark Laboratories

Table 30: Parasitological and clinical responses after nitazoxanide treatment (100 mg bid for 3 days) of clinically ill patients or patients who continued to shed oocysts with prior placebo or nitazoxanide treatments.

Previous Treatment group	Patient ID	Clinical response after first treatment	Oocysts in stool sample after first treatment UC (C)	Oocysts in stool samples on different days after initiation of therapy UC (C)							Parasitologic response	Clinical response	
				7	8	9	10	11	12	13			
Placebo b.i.d 3 days	2#	well	+ (ND) / - (0)		- (0)							Eradicated	well
	24	CI	- (ND)					- (ND)			+ (1+)		well
	27#	CI	- (ND)		- (0)							Eradicated	well
	39	CI	+ (1+)	Lost to follow-up									
	47	CI	+ (2+)		+ (1+)								well
	29	CI	+ (1+)		- (0)					- (0)		Eradication	well
	22	CI	+ (3+)		- (0)	+ (1+)							well
NTZ 100 mg b.i.d 3 days	1#	CI	- (0)		- (0)							Eradicated	well
	5	CI	+ (ND)		- (0)	- (0)						Eradicated	well
	11	CI	+ (1+)	- (0)	+ (1+)								well
	13	CI	+ (1+)		- (0)	- (0)						Eradicated	well
	23	CI	- (0)		- (0)	- (0)						Eradicated	CI
	31	CI	- (0)		+ (1+)	+ (1+)							well
	41	CI	- (0)		- (0)	- (0)						Eradicated	well
	48	CI	+ (1+)		+ (1+)	- (0)							well
	21	well	+ (1+)	- (0)				- (0)				Eradicated	well
	18	well	+ (2+)	+ (2+)	+ (1+)								well
	30	CI	+ (1+)		+ (1+)	+ (1+)							well
	33	CI	+ (1+)		+ (1+)	+ (1+)							CI

NTZ = Nitazoxanide; UC = unconcentrated stool; C = concentrated stool; + = positive result;
 - = negative result; ND = Not done; CI = continuing illness;
 # one stool sample examined
 0 = no oocyst entire smear;
 1+ = <5 oocyst per microscopic field (100X magnification);
 2+ = <5 oocyst per microscopic field (100X magnification)

In study RM02-3008, 50 HIV positive children (≤ 11 years) with *C. parvum* infection were enrolled. The inclusion/exclusion criteria, methods of detection of *C. parvum* and HIV, and the primary and secondary endpoints were same as those for study RM02-3007. Of the 50 children enrolled, one child (>3 years old) received 200 mg NTZ while others received 100 mg NTZ twice a day for 3 days.

The results in Table 31 show that nitazoxanide (100 mg bid for 3 days) was not effective in the treatment of *C. parvum* infections in HIV positive children. No attempts were made to analyze the relationship between the number of CD4 cells and parasite clearance or clinical response as the CD4 cell counts for majority of the children was not available.

Cryptaz
Romark Laboratories

Table 31: Efficacy of nitazoxanide in HIV positive children with *C. parvum* infection (RM02-3008).

Treatment group	Age in years	baseline parasite score (no of subjects)	No. of patient		Parasitologic and clinical response		Patients with eradication of oocysts N (%)	Clinical well response N (%)	Patients clinical well and eradicated oocysts N (%)
			total	excluded	Eradicated (CR)	Persisted (CR)			
Placebo b.i.d 3 days	1-3	≤ 2+ (13) ≤ 4+ (9) NA (3)	25	1	3 (well); 2 (CI)	3(well); 16 (CI)	5 (21)	6 (25)	3 (13)
100 mg NTZ b.i.d 3 days	1-3	≤ 2+ (11) ≤ 4+ (8) NA (5)	24	0	1 (well); 2 (CI)	1(well); 20 (CI)	3 (12)	2 (8)	1 (4)
200 mg NTZ b.i.d 3 days	4-11	2+	1			1 (CI)	0 (0)	0 (0)	0 (0)

NTZ = Nitazoxanide
NA = not available
CR = clinical response
N = number of subjects

Parasite score: 0 = no oocyst entire smear;
2+ = <5 per microscopic field (100X magnification)
3+ = 5-10 per microscopic field (100X magnification)
4+ = 11-20 per microscopic field (100X magnification)

In summary, the parasitologic outcome in the three clinical trials conducted to determine the efficacy of nitazoxanide in the treatment of cryptosporidial diarrhea in children and adults was limited to microscopic examination of oocysts in stained smears using small amount of stool samples. Concentrated stool samples were not used consistently across the 3 studies. In few patients the results of the staining were confirmed by immunofluorescence. Use of two different methods (such as ZNN and IFA) improved the detection of oocyst. In immunocompetent patients with cryptosporidial diarrhea, absence of oocysts in stool samples at 6 to 23 days after initiation of therapy and resolution of clinical symptoms was observed in 24/60 (40%) patients treated with nitazoxanide compared to 5/67 (7%) patients in the placebo arm. There appears to be a lack of correlation between the clinical and parasitological outcomes of patients (except in children 4-11 years of age) after treatment with nitazoxanide. In HIV positive immunocompromised children, nitazoxanide at a dose of 100 mg b.i.d for 3 days was ineffective in the treatment of cryptosporidial diarrhea.

B. *Giardia lamblia*:

1.1. Biology of *Giardia lamblia*:

Giardia lamblia is a flagellated protozoan found in intestinal tract of human. It is also referred to as *Giardia duodenalis* or *Giardia intestinalis*. Infection is caused by ingestion of contaminated food or water containing *G. lamblia* cysts. Following ingestion, the cysts pass through the stomach to the small intestine where they excyst to give rise to trophozoites. The trophozoites attach to the epithelial cells in the duodenum and bile duct of the host, divide by longitudinal fission and encyst on reaching the colon. In cases of severe infection, trophozoites are more commonly observed than cysts in diarrheic stool samples.

Cryptaz
Romark Laboratories

1.2. Pathogenesis of Giardiasis:

The major clinical manifestations of *Giardia lamblia* infection are diarrhea and malabsorption. Although changes in the villi of the intestine have been observed, the mechanism by which *Giardia* causes diarrhea is not known. The host immune response plays an important role in protection from the infection. In addition to the immune status of the host, the severity and duration of the infection can be affected by the number of cysts ingested and the strain of *Giardia*.

2. MECHANISM OF ACTION:

The ability of nitazoxanide to act as an electron acceptor for the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme of *G. lamblia* was examined¹. The PFOR enzyme catalyzes the conversion of pyruvate to acetylCoA and carbon dioxide (CO₂) using ferredoxin as an electron acceptor. This conversion can be monitored spectrophotometrically using alternate electron acceptors. For measuring PFOR activity, log phase cultures of *G. lamblia* grown in Diamond's TYI-S-33 medium were harvested, disrupted by using a glass homogenizer and fractions obtained by centrifugation. The soluble fraction (supernatant obtained after centrifugation at 14,000 x g) was incubated in the presence of pyruvate and nitazoxanide under aerobic and anaerobic conditions (by bubbling hydrogen in the cuvette) and the reduction of nitazoxanide measured at 412 nm spectrophotometrically. Comparison was made using a known electron acceptor (redox active dye, benzyl viologen) by measuring absorbance at 546 nm. The results in Table 32 show an increase in specific activity in the presence of nitazoxanide thereby suggesting that nitazoxanide could serve as an electron acceptor for the *G. lamblia* PFOR enzyme. The specific activity for nitazoxanide was 11 to 38 fold higher than benzyl viologen. The end products (acetyl-CoA and CO₂) of the enzymatic reaction were not measured. Therefore, the ability of nitazoxanide to inhibit PFOR activity is not known.

Table 32: PFOR activity of *Giardia intestinalis* using benzyl viologen and nitazoxanide as electron acceptor.

	Specific Activity (nmol/min/mg P)	
	Benzyl viologen	Nitazoxanide
Without H ₂	124.7	1,411
With H ₂	128	4,829

The DNA derived PFOR protein sequence of *G. lamblia* was shown to be 31% similar to that of *C. parvum*¹.

3. ACTIVITY IN VITRO:

The *in vitro* activity of nitazoxanide against *Giardia lamblia* was measured using different methods, namely, incorporation of ³H-thymidine and inhibition of adherence by two different investigators.

Cryptaz

Romark Laboratories

In one study^{15,16}, the *in vitro* activity of nitazoxanide and its metabolites against 6 strains of *G. lamblia* was examined using log phase cultures of *G. lamblia* containing trophozoites. The trophozoites (10^4) were incubated with two fold dilutions of drugs in Diamond's TYI-S-33 complete medium supplemented with 10% inactivated bovine serum and 3% Vitamin-Tween 80 mixture for 24 hours at 35°C in 4% CO₂. The activity of the drug was measured by incorporation of ³H-thymidine and the incubation was continued for an additional 24 hours. Metronidazole was used as a comparator. The drug concentration required for 50% inhibition of parasites (IC₅₀) was determined by regression analysis. The raw data for the parasite counts were not shown. The results in Table 33 show that nitazoxanide IC₅₀ values against the 6 strains varied from 1.07 to 7.81 μM (3.5 to 25.4 μg/ml). The nitazoxanide IC₅₀ values were 2 to 5 fold lower than metronidazole (Table 33). Tizoxanide had similar activity to nitazoxanide, however, tizoxanide glucuronide was 2-30 fold less active than nitazoxanide (Table 33). Motility or other viability tests were not performed.

The IC₅₀ values for nitazoxanide and the metabolites against the *G. lamblia* JKH-1 strain were higher than the other strains (Table 33). This strain was originally isolated from a patient with chronic infection refractory to metronidazole.

Table 33: *In vitro* activity of nitazoxanide and its metabolites against *Giardia lamblia* (Experiment was performed 3 times in duplicate).

Mean IC ₅₀ μM [SD]				
Strain	MTZ	NTZ	TIZ	TIZg
EBC	4.55 [2.2]	1.07 [0.7]	0.716 [0.3]	11.87 [0.6]
EBE	5.95 [5.8]	2.25 [2.5]	0.641 [0.5]	4.28 [1.2]
VNB1	5.72 [3.4]	1.17 [1.1]	0.603 [0.2]	33.2 [0.9]
VNB2	3.21 [1.2]	1.20 [0.9]	0.528 [0.4]	15.22 [1.9]
VNB5	5.20 [3.5]	1.69 [0.9]	0.641 [0.4]	14.66 [5.4]
JKH-1	15.42 [4.3]	7.81 [1.7]	8.18 [1.4]	14.00 [1.3]
MEAN	6.68[4.4]	2.53[2.62]	1.89[3.1]	15.54[9.5]
MEAN(-JKH-1)	4.93 (1.1)	1.48 [0.49]	0.63 [0.07]	15.85 [10.6]
t-test vs MTZ	-	NS	NS	NS
t-test vs MTZ (-JKH-1)	-	0.000929	0.000918	NS

MTZ = metronidazole

NTZ = nitazoxanide

TIZ = tizoxanide

TIZg = tizoxanide glucuronide

In another study¹⁷, the *in vitro* activity of nitazoxanide and tizoxanide against the metronidazole sensitive (netronidazole IC₅₀ not specified) and metronidazole resistant (netronidazole IC₅₀ >200 μg/ml) strains of *Giardia lamblia* was examined by an adherence assay. Metronidazole and albendazole were used as comparators. About 5 x 10⁵ trophozoites (obtained after infecting Mongolian gerbils with cysts) suspended in MHSP3 medium with or without drug were added to 12 day old monolayers of Caco-2 cells in DMEM supplemented with 1% non essential amino acids and 20% fetal calf serum for 1 hour at 37°C in 5% CO₂ to allow for adherence (parasite:cell ratio 1:10). The non-adherent parasites were removed by washing the cultures with fresh MHSP3 medium and the adherent parasites were collected after incubation of the monolayer with ice-cold Ca²⁺/Mg²⁺ free phosphate buffered saline (PBS; pH 7.4) for 10 minutes and washing with the same solution. The total number of adherent trophozoites were counted microscopically (sample volume was not specified) and the percent adherence was calculated as follows:

Cryptaz
Romark Laboratories

$$\% \text{ adherence} = \frac{\text{adherence in drug treated culture}}{\text{adherence in untreated culture}} \times 100$$

The toxic effects of nitazoxanide and tizoxanide on Caco-2 cells were not examined. The mean % adherence of _____ strains to Caco-2 cells were 80.4%, 80.2 and 81.3%, respectively. The results in Table 34 show that the % adherence of the 3 *G. lamblia* strains in the presence of nitazoxanide and tizoxanide (10 µg/ml) was 12-30% lower than the controls. Similar observations were made with albendazole and metronidazole.

Table 34: Effect of drugs on the adherence of *Giardia* trophozoites to Caco-2 cells (% vs control).

Drug	Dose (µg/ml)	Isolates		
		_____	_____	_____
	10	75.9	91.1	73.9
METRONIDAZOLE	50	74.6	55.5	57.1
	100	67.4	37.5	45.6
	10	70.9	86.2	83.4
ALBENDAZOLE	50	55.5	79.	76.6
	100	47.3	53.2	28.3
	10	86.7	85.8	58.8
TIZOXANIDE	50	66.4	57.4	50.8
	100	35.9	44.8	38.4
	10	69.6	88.1	84.9
NITAZOXANIDE	50	60.0	59.0	53.7
	100	30.3	36.9	41.3

The drug concentration required to reduce the adherence of trophozoites to the cell-line by 50% (IC₅₀) was calculated by regression analysis. The nitazoxanide IC₅₀ values against the 3 isolates varied between 61 and 74 µg/ml and the tizoxanide IC₅₀ values varied between 50 and 82 µg/ml (Table 35). These IC₅₀ values were 3 to 18 fold higher than that observed in the previous study. Since the methods for susceptibility testing of *Giardia* are not standardized and in the absence of toxicity data, the significance of these IC₅₀ values in determining activity of the drug is not known.

Table 35: Effect of drugs on the adherence of *Giardia* trophozoites to Caco-2 cells (Inhibitory concentration 50).

Drug	MIC ₅₀ (µg/ml) for Isolates		
	Rouen/98/Epe/1	Rouen/98/Epe/2	Rouen/98/Epe/3
METRONIDAZOLE	>200	72.7	81.8
ALBENDAZOLE	84	114.4	84.8
TIZOXANIDE	76.3	81.6	50.3
NITAZOXANIDE	60.7	73.4	74.3

4. ACTIVITY IN VIVO:

Five day old neonatal SPF NMRI mice were infected orally with 10³ trophozoites of the _____ strain of *G. duodenalis*¹⁸. Single doses of nitazoxanide, metronidazole or albendazole (10, 50 100 and 200 mg/kg) were administered by the oral route, 5 days after infection. Vehicle treated animals were used as controls. Mice were necropsied 48 hours after treatment and the small intestine removed and placed in NCTC 135 medium for 10 minutes

Cryptaz

Romark Laboratories

before shaking to detach the parasites. The parasites were separated from the tissue by filtration and counted using a hemocytometer. The results in Table 36 show the trophozoite counts in the control group to vary from 14 to 330. Based on these results the % trophozoite counts in drug treated animals compared to control animals was calculated and used to determine the 50% effective dose (ED₅₀) by regression analysis (Table 37). The ED₅₀ values for nitazoxanide, metronidazole and albendazole were 31.2 mg/kg, 125.8 mg/kg and 44.2 mg/kg, respectively. The sponsor has stated that the 100 mg/kg and 200 mg/kg dose of nitazoxanide was effective in the treatment of infected animals. However, this effect may not be significant due to the variation in the trophozoite counts observed in the control groups.

Table 36: Number of trophozoites per ml in untreated control (C) and treated (T) newborn mice.

Mice	Metronidazole						Nitazoxanide						Albendazole							
	10		50		100		10		50		100		10		50		100		200	
	C	T	C	T	C	T	C	T	C	T	C	T	C	T	C	T	C	T	C	T
1																				
2																				
3																				
4																				
5																				
6																				
7																				
8																				
m	33.7	37.8	30.2	22.7	46.1	28.7	143	25	48	28.6	17.2	7.7	100	25.5	30.2	3.6	227	158	106	43.7
±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±
sd	2.6	3	3.9	3.1	3.9	2.7	8	2.6	3.7	4.3	1.8	1.8	8.6	1.7	3.2	0.8	40.7	17.4	7.8	6

Table 37: Effects of drugs on new born mice infection (% trophozoite count compared to control animals).

Dose (mg/kg)	Metronidazole	Nitazoxanide	Albendazole
10	112.6 ± 8.9	59.6 ± 8.9	69.6 ± 7.6
50	75.1 ± 10.2	44.9 ± 10.4	41.2 ± 5.7
100	62.2 ± 5.8	25.3 ± 1.7	26.2 ± 10.7
200	17.4 ± 1.8	11.8 ± 2.5	0.8 ± 0.8

No other studies were done to measure the activity of nitazoxanide *in vivo*.

5. CLINICAL MICROBIOLOGY:

5.1. Diagnosis of Giardiasis:

Diagnosis of Giardiasis is based on detection of trophozoites or cysts by microscopic examination of unconcentrated and concentrated stool samples. Since the trophozoites attach to the duodenal walls and the cysts are shed intermittently in stool, the possibility of missing the parasites exists. Staining of fecal smears is recommended as it improves the sensitivity of the microscopic examination. Beside microscopic examination, immunofluorescence and enzyme linked immunosorbent assays are available for the detection of *Giardia* cysts and have been shown to be more sensitive than microscopic examinations. Although these tests need specialized equipment, they are easy to perform and less prone to error. In cases where stool samples are negative, testing of duodenal aspirates or duodenal contents using the Entero-test capsule (the capsule contains a string that can be used to retrieve duodenal contents) may be useful to rule out infection.

Cryptaz

Romark Laboratories

Methods detecting anti-*Giardia* IgG antibodies have been used more for epidemiological purposes than diagnosis due to the prolonged persistence of the antibodies in circulation. PCR methods have been developed for detection of *Giardia* cysts, however, the usefulness of PCR for diagnosis and evaluation of drug efficacy is not known.

5.2. Clinical studies:

Two randomized studies (RM-NTZ-98-001 and RM-NTZ-99-010) were conducted in Egypt and Peru to examine the safety and efficacy of nitazoxanide in the treatment of giardiasis.

In study RM-NTZ-98-001, about 100 adults (12 - 65 years) from Egypt, with diarrhea (> 4 bowel movements/day with or without other symptoms such as bloody stools, rectal bleeding or enlarged colon) and positive for cysts or trophozoites of *Giardia lamblia* and/or *Entamoeba histolytica/dispar* in stool samples within 7 days prior to enrollment were included. This was a randomized, placebo controlled, double-blind study. Subjects receiving other antiparasitic or antihelminthic drugs, those with hypersensitivity to nitazoxanide or nitroimidazole, and those who tested HIV positive (using the _____apid Test) were excluded. Subjects were treated with nitazoxanide (500 mg, b.i.d) or placebo for 3 days. The primary endpoints of the study were (a) resolution of clinical symptoms, and (b) absence of cysts or trophozoites in two stool samples (unconcentrated and/or concentrated) collected atleast 24 hours apart between days 6 and 13 after initiation of treatment. The secondary endpoint was time to passage of last unformed stool.

The diagnosis of *G. lamblia* and *E. histolytica* was made using the _____ test (FDA approved), an enzyme immuno assay for detection of cysts of *G. lamblia* and *E. histolytica* and oocysts of *C. parvum*. These results were confirmed by microscopic examination of unconcentrated and/or concentrated stool samples (400x magnification over the entire cover slip area). In addition to these tests, the _____ immunofluorescence assay (FDA approved for diagnosis of *G. lamblia* cysts in stool samples) was used in some cases. All these methods except the _____ test were used for parasitological evaluations of post-treatment samples. The quantity of stool for direct examination was not specified, however, 5 gram of formed stool or 0.5 ml of watery stool was used for concentration by the formalin-ether method. The methods used for identification of other protozoans/helminths are shown in Table 22 (page 33).

The efficacy analysis for patients with infections due to *G. lamblia* alone, *G. lamblia* and *E. histolytica*, and *E. histolytica* alone at baseline, was performed separately. A total of 22 patients (11 per treatment arm) had infection due to *G. lamblia* alone at baseline. Few patients had mixed infection with *B. hominis* and were excluded from analysis. Patients who did not return for follow-up visit and those who discontinued from the study were considered as failures.

The results in Table 38a suggest the concentration and immunofluorescence methods were more sensitive in the detection of *Giardia* cysts than examination of unconcentrated stool when the cysts were present in low numbers. In addition, examination of two or more stool samples is helpful for evaluation of drug efficacy. For example, only one of the two stool samples were positive for cysts in 5/10 (50%) patients in the placebo arm (Table 38a) and 1/11 (9%) patients in

Cryptaz

Romark Laboratories

the nitazoxanide arm (Table 38b). It is of note that trophozoites were detected in one patient (#42) in the nitazoxanide arm at the post-treatment visit (Table 38b).

The parasitological and clinical responses of patients with giardiasis to nitazoxanide treatment are summarized in Table 39. In patients with infection due to *Giardia* alone (n = 8), 6 patients were clinically well and did not show presence of cysts after treatment with nitazoxanide (500 mg b.i.d for 3 days; Tables 38b and 39). Two patients were clinically well but continued to shed cysts. In the placebo arm, none of the 10 patients were cured of the parasite although 3 were clinically well (Tables 38a and 39). The time of evaluation of the clinical response was not specified. Based on a small number of patients, nitazoxanide (500 mg, b.i.d for 3 days) appears to be effective in the treatment of giardiasis in adults.

Table 38a: Parasitological and clinical responses of adults with *G. lamblia* infection in the placebo arm (study RM-NTZ-98-001).

Patient ID	Cysts in baseline stool sample UC (C) [IFA]	Cysts in stool samples on different days after initiation of therapy UC (C) [IFA]						Parasitologic response	Clinical response		
		5	6	7	8	9	11			13	
27	0-2 (0-4) [6-8]								Failed	CI	
37	- (-) [0-2]		- (6-10) [+]						- (-) [-]	Failed	CI
38	- (2-3) [0-3]									Failed	CI
41	0-2 (1-3) [-]		- (-) [0-3]		- (-) [-]					Failed	CI
45	2-6 (6-12) [+]			0-3 (3-6) [5-10]					- (-) [-]	Failed	CI
47	- (-) 5-8		- (-) [-]			0-1 (0-1) [5-8]				Failed	CI
56	2-6 (6-10) [5-10]			1-3 (2-3) [ND]				+	(+) [ND]	Failed	Well
68	0-2 (2-4) [ND]		- (-) [ND]					-	(3-5) [ND]	Failed	Well
74*	1-2 (3-5) [ND]		0-1 (3-5) [ND]							Failed	Well
75	1-3 (3-9) [ND]		1-3 (3-5) [ND]							Failed	CI
88	1-3 (3-6) [ND]	- (1-3) [ND]								Failed	Well

* excluded due to *B. hominis* infection
 IFA = merifluor immunofluorescence;
 ND = Not done

UC = unconcentrated stool;
 - = negative result
 CI = ccontinuous illness

C = concentrated stool;
 + = positive result

Cryptaz

Romark Laboratories

Table 38b: Parasitological and clinical responses of adults with *G. lamblia* infection in the nitazoxanide arm (study RM-NTZ-98-001).

Patient ID	Cysts in baseline stool sample UC (C) [IFA]	Cysts in stool samples on different days after initiation of therapy UC (C) [IFA]						Parasitologic response	Clinical response
		6	7	8	11	12	13		
8	6-10 (8-15) [30]	- (-) [-]			- (-) [-]			Eradicated	Well
9	15-20 (15-20) [30]	- (-) [-]			- (0-1) [-]			Failed	Well
32*	(-) [0-1]	(-) [-]		(-) [-]				Eradicated	Well
33	- (-) [0-1]	- (-) [-]		- (-) [-]				Eradicated	Well
42**	2-4 (2-5) [5-15]	- (-) [1-3]		0-3 (3-10) [15-20]				Failed	Well
46	- (0-1) [-]	- (-) [-]					- (-) [-]	Eradicated	Well
50	- (-) [1-3]				- (-) [ND]	- (-) [ND]		Eradicated	Well
55	- (-) [0-2]	- (-) [ND]		- (-) [ND]				Eradicated	Well
71	0-2 (3-5) [ND]		- (-) [ND]	- (-) [ND]				Eradicated	Well
78*	(3-5) [ND]	(-) [ND]					(-) [ND]	Eradicated	Well
80*	(3-5) [ND]	(-) [ND]		(-) [ND]				Eradicated	CI

* excluded due to *B. hominis* infection

UC = unconcentrated stool;

- = negative result

ND = Not done

** 0-1 trophozoites observed in one unconcentrated stool sample;

C = concentrated stool;

IFA = merifluor immunofluorescence;

+ = positive result

CI = continuous illness

Table 39: Summary of parasitological and clinical responses of adults with *G. lamblia* infection at days 5 - 13 after treatment with nitazoxanide (for 3 days).

Treatment group	No. of patient		Parasitological and clinical responses		Patients with eradication of cysts N (%)	Patients with clinical well response N (%)	Patients clinical well and showing eradication of cysts N (%)
	total	excluded	Cysts Eradicated (CR)	Cysts Persisted (CR)			
Placebo b.i.d 3 days	11	1	0	3 (well); 7 (CI)	0 (0)	3 (30)	0 (0)
500 mg NTZ b.i.d 3 days	11	3	6 (well)	2 (well)	6 (75)	8 (100)	6 (75)

NTZ = Nitazoxanide;

CR = clinical response;

N = number of subjects;

CI = continuing illness.

Of the 14 patients with infection due to *G. lamblia* and *E. histolytica* at enrollment, 8 were treated with placebo and 6 with nitazoxanide (500 mg b.i.d for 3 days). Parasitological and clinical cure

Cryptaz

Romark Laboratories

for both parasites was observed in one patient (Table 40, shown in bold). Three patients showed eradication of *Giardia* cysts but only one was clinically well. Although one patient treated with placebo resolved diarrhea, parasitological cure was not observed (Table 40).

Table 40: Summary of parasitological and clinical responses of adults with mixed *G. lamblia* and *E. histolytica* infection at days 5 -13 after treatment with nitazoxanide (for 3 days).

Treatment group	No. of patient		Parasitological and clinical responses		Patients with eradication of <i>Giardia</i> cysts N (%)	Patients clinical well response and eradication of <i>Giardia</i> cysts N (%)
	total	excluded	Cysts Eradicated (CR)	Cysts Persisted (CR)		
Placebo b.i.d 3 days	8	3	2 ^a (CI)	1 ^f (well); 2 ^f (CI), 2 ^e (CI)	0 (0)	0 (0)
500 mg NTZ b.i.d 3 days	6	0	1 ^c (well)*, 1 ^a (well); 1 ^c (CI), 1 ^b (CI)	2 ^f (well), 1 ^e (well); 1 ^d (CI)	3 (50)	1 (17)

NTZ = Nitazoxanide;

^a eradicated Amoeba cysts;

^b eradicated *Giardia* cysts;

^c eradicated Amoeba and *Giardia* cysts

*eradicated Amoeba and *Giardia* cysts and clinically well;

N = number of subjects

CI = continuing illness

^d persisting amoebiasis

^e persisting giardiasis

^f persisting amoebiasis and giardiasis

CR = clinical response

A total of 55 patients with amoebiasis were enrolled. The results in Table 41 show that treatment with nitazoxanide (500 mg b.i.d for 3 days) eradicated the *E. histolytica* cysts in 19/25 (76%) patients and resolved diarrhea in 17 of the 19 patients. However, placebo was also effective in eradicating cysts in 9/20 (45%) patients and resolving diarrhea in 8 of these 9 patients. Although, 4 patients in the nitazoxanide arm and one in the placebo arm were clinically well, they continued to shed *E. histolytica* cysts. There appears to be a correlation between the parasitological and clinical outcomes in both groups.

Table 41: Summary of parasitological and clinical responses of adults with *E. histolytica* infection at days 5 -13 after treatment with nitazoxanide (for 3 days).

Treatment group	No. of patient		Parasitological and clinical responses		Patients with eradication of cysts N (%)	Patients with clinical well response N (%)	Patients clinical well and eradicated cysts N (%)
	total	excluded	Cysts Eradicated (CR)	Cysts Persisted (CR)			
Placebo b.i.d 3 days	24	4	8 (well); 1 (CI)	1 (well); 10 (CI)	9 (45)	9 (45)	8 (40)
500 mg NTZ b.i.d 3 days	31	6	17 (well); 2 (CI)	4 (well); 2 (CI)	19 (76)	21 (84)	17 (68)

NTZ = Nitazoxanide

CR = clinical response

CI = continuing illness

N = number of subjects

Overall, the concentration and immunofluorescence methods appear to be more sensitive in the detection of *Giardia* cysts than examination of unconcentrated stool when the cysts were present in low numbers. Examination of 2 or more samples is necessary for evaluation of drug efficacy,

Cryptaz

Romark Laboratories

as the shedding of cysts in the stool can be intermittent. Nitazoxanide was effective in the treatment of 6/8 adults with giardiasis compared to placebo (0/10 adults). Of the 6 patients with mixed *Giardia* and *Entamoeba* infections, eradication of both parasites and resolution of diarrhea was observed in one patient after treatment with nitazoxanide. Eradication of *E. histolytica* cysts and resolution of diarrhea was observed in 68% (17/25) amoebiasis patients treated with nitazoxanide compared to 40% (8/20) patients in the placebo arm. Nitazoxanide appears to be more effective than placebo in the treatment of amoebiasis. However, the number of patients with giardiasis or amoebiasis enrolled in the study was too small.

In study RM-NTZ-99010, 110 children (2-11 years old) from Peru with acute diarrhea (> 3 unformed stools/day) or chronic diarrhea (unformed stools with or without increased stool frequency for more than 4 weeks) and positive for *Giardia lamblia* in stool samples by the enzyme immunoassay were included. The initial diagnosis for *Giardia* by the enzyme test at screening was confirmed by microscopic examination of unconcentrated and/or concentrated stool samples at baseline. The exclusion criteria were same as study RM-NTZ-98-001 except patients with *E. histolytica* and *C. parvum* infections were also excluded. The post-treatment diagnosis was made by microscopic examination of unconcentrated and concentrated stool samples, however, the cysts/trophozoites were not quantified. The primary endpoint was resolution of clinical symptoms. The secondary endpoints were (a) absence of cysts or trophozoites in two stool samples (unconcentrated and/or concentrated) collected at least 24 hours apart between days 7 and 16 after initiation of treatment, (b) time to passage of last unformed stool, and (c) therapeutic cure (clinically well and absence of parasite).

For the efficacy analysis, patients with mixed infections and those who did not take all the doses of the medication were excluded. The results in Table 42 show that nitazoxanide was as effective as metronidazole in the treatment of *Giardia lamblia* infection in children. In children with giardiasis, there appears to be a correlation between the parasitological and clinical outcomes after treatment with nitazoxanide or metronidazole.

Table 42: Parasitological and clinical responses of children with *G. lamblia* infections to nitazoxanide or metronidazole treatment.

Treatment group	Age in years	No. of patient		Parasitological and clinical responses		Patients with eradication of cysts N (%)	Patients with clinical well response N (%)	Patients clinical well and eradicated cysts N (%)
		total	excluded	Eradicated (CR)	Persisted (CR)			
Metronidazole (125 mg) b.i.d 3 days	1-3	11	4	6 (well)	1 (CI)	6 (86)	6 (86)	6 (86)
100 mg NTZ b.i.d 3 days	1-3	14	2	9 (well)	2 (well); 1 (CI)	9 (75)	11 (92)	9 (75)
Metronidazole (250 mg) b.i.d 3 days	4-11	44	11	21 (well); 4 (CI)	5 (well); 3 (CI)	25 (76)	26 (79)	21 (64)
200 mg NTZ b.i.d 3 days	4-11	41	15	20 (well); 3 (CI)	2 (well); 1 (CI)	23 (89)	22 (85)	20 (77)

NTZ = Nitazoxanide;

N = number of subjects;

CR = clinical response;

CI = continuing illness;

Cryptaz

Romark Laboratories

In summary, parasitological evaluations in the clinical trials conducted to determine efficacy of nitazoxanide in the treatment of giardiasis was based on microscopic examination of unconcentrated and/or concentrated wet stool samples. Fixed fecal smears after staining (known to improve sensitivity of parasite detection) were not examined. In one study (RM-NTZ-98-001), the immunofluorescence assay was used to confirm the diagnosis. No other assay was used for confirmation in the other study (RM-NTZ-99-010). Concentration and immunofluorescence detection methods were more sensitive when the number of cysts in the stool was low. Additionally, examination of 2 or more stool samples was useful for evaluation of parasitological efficacy. Nitazoxanide was as effective as metronidazole in the treatment of children with giardiasis in Peru. Nitazoxanide was also effective in adults with *G. lamblia* infection in Egypt compared to placebo.

C. Protozoa (other than *Cryptosporidium* and *Giardia*), Helminths or Bacteria:

2. MECHANISM OF ACTION:

2.1. Protozoa:

The ability of nitazoxanide to act as an electron acceptor for the PFOR enzyme of *Entamoeba histolytica* and *Trichomonas vaginalis* was examined under aerobic conditions¹. For this, the parasites were grown to log phase in Diamond's TYI-S-33 medium and then harvested, disrupted by sonication or by using a glass homogenizer and fractions obtained by centrifugation. The soluble fraction of the *E. histolytica* cell extract (supernatant obtained after centrifugation at 14,000 x g) was used to measure enzyme activity. In the case of *T. vaginalis*, the fraction containing hydrogenosomes (supernatant obtained after centrifugation at 100,000 x g) was used. The fractions were incubated in the presence of the pyruvate (substrate) and nitazoxanide and the absorbance was measured at 412 nm. Other electron acceptors (redox active dye) such as benzyl viologen and nitroblue tetrazolium were used as comparators. The absorbance of products of benzyl viologen and nitroblue tetrazolium reduction was measured at 546 nM. The results in Table 43 show that the specific activity of the *E. histolytica* PFOR enzyme in the presence of nitazoxanide was about 2-fold less than that observed in the presence of benzyl viologen and 17-fold more than that observed in the presence of nitroblue tetrazolium. The results suggest that nitazoxanide acts as an electron acceptor for the *E. histolytica* PFOR enzyme. Nitazoxanide was a better electron acceptor than nitroblue tetrazolium. However, benzyl viologen was the best electron acceptor for the enzyme.

Table 43: PFOR activity in *Entamoeba histolytica* with different electron acceptor.


Electron acceptor	Specific activity (nmol/min/mg protein)
benzyl viologen	1,485
nitroblue tetrazolium	37
nitazoxanide	645

Cryptaz

Romark Laboratories

The ability of nitazoxanide to act as an electron acceptor was also examined under anaerobic conditions using benzyl viologen (5 mM). For this, the soluble fraction was incubated in the presence of pyruvate, benzyl viologen and different concentrations of nitazoxanide and activity of PFOR measured spectrophotometrically at 546 nm. Anaerobic condition in the cuvettes was achieved by bubbling H₂ gas or by addition of sodium dithionite. The results in Figure 18 show that nitazoxanide ($\geq 42 \mu\text{M}$ i.e., 13 $\mu\text{g/ml}$) decreased the ability of *E. histolytica* PFOR enzyme to reduce benzyl viologen, suggesting that nitazoxanide can compete with benzyl viologen as the electron acceptor.

Figure 18: Nitazoxanide inhibition of benzyl viologen reduction in *E. histolytica*.



Series 1: H₂ bubbled to make cuvette anaerobic

Series 2: Sodium hydrosulfite (dithionite) used instead of hydrogen to render cuvette anaerobic

Using the same assay, nitazoxanide, at a concentration of 20 μM (i.e. 6 $\mu\text{g/ml}$), was shown to compete with benzyl viologen for electrons and act as an electron acceptor for the PFOR enzyme from 2 strains of *T. vaginalis* (Table 44).

Table 44: Effect of nitazoxanide on inhibition of PFOR activity in *T. vaginalis*.

Strain	Benzyl viologen reduction (nmol/min/mg protein)		Percent inhibition
	0 μM nitazoxanide	20 μM nitazoxanide	
014 (metronidazole-sensitive)	105	5.12	95%
043 (metronidazole-resistant)	113	20.5	82%

2.2. Anaerobic and microaerophilic bacteria:

The ability of nitazoxanide to act as an electron acceptor for the PFOR enzyme of *Clostridium difficile* and *Clostridium perfringens* was examined¹. For this, one strain of each of the 2 species was grown in Wilkins-Chalgreen broth under anaerobic conditions for 24 hours. Cell-free extracts were prepared and used to test for PFOR activity by the same assay as described in the previous study. The results in Table 45 show 3 to 4 fold increase in specific activity of PFOR in


the presence of nitazoxanide compared to benzyl viologen suggesting that nitazoxanide can serve as an electron acceptor for the PFOR enzyme of *Clostridium*.

Table 45: PFOR activity for *Clostridium difficile* and *Clostridium perfringens*.

	Specific Activity (nmol/min/mg P)	
	Benzyl viologen	Nitazoxanide
<i>Clostridium difficile</i>	211	638
<i>Clostridium perfringens</i>	450	1,920


The mechanism by which nitazoxanide exhibits activity against *Helicobacter pylori* was examined under anaerobic conditions^{19,20}. Cell extract prepared from late log phase cultures of *H. pylori* grown in Brucella broth was used to determine PFOR activity. The PFOR activity was measured spectrophotometrically at 546 nm using benzyl viologen as described in the previous studies. However, the reaction mixture also contained coenzyme A and thiamine pyrophosphate (additional co-factors required for enzyme activity). Anaerobic condition was achieved by adding few grains of sodium hydrosulfite to the reaction mixture. The reduction of benzyl viologen by PFOR in the presence of nitazoxanide (0-32 µg/ml) was determined. The results in Figure 18 show that nitazoxanide inhibits the reduction of benzyl viologen by PFOR, suggesting that it can act as an alternative electron acceptor for the PFOR enzyme of *H. pylori*.

Figure 18: Competitive inhibition of PFOR activity (benzyl viologen reduction) in *H. pylori* extracts as a function of NTZ concentration. POR = PFOR= pyruvate oxidoreductase.



In another experiment, the ability of nitazoxanide to act as an electron acceptor for PFOR enzyme was measured spectrophotometrically at 412 nm. The results in Figure 19 show a decrease in absorbance at 412 nm suggesting that nitazoxanide is reduced. This confirms the observation made in the previous experiment that nitazoxanide can act as an electron acceptor for the PFOR enzyme of *H. pylori*.

Figure 19: PFOR assay by monitoring reduction of nitazoxanide at 412 nm.



The role of other enzymes such as nitroreductases (e.g., RdxA and FrxA) in the reduction/activation of nitazoxanide was investigated in *H. pylori*. In one study¹⁹, the minimum inhibitory concentration (MIC) required to completely inhibit growth of *H. pylori* in the presence of the *rdxA* gene was 8-fold lower than in its absence. Such testing was done by the standard agar dilution method using Brucella agar medium supplemented with 7% fetal bovine serum under microaerobic conditions at 37°C (Table 46). The results suggest that bacteria with *rdxA* gene were susceptible to nitazoxanide and that this gene may be involved in the activation of the drug.

Table 46: Role of RdxA in susceptibility to nitazoxanide.

Strain	MIC (µg/ml)	
	Metronidazole	Nitazoxanide
1061 (<i>rdxA</i> -ve mutant)	64	32
1061 + pRdxA*	1	4

*Strain 1061 with plasmid carrying wild-type RdxA.

In another study²⁰, the ability of two nitroreductases (encoded by the *rdxA* and *frxA* gene) of *H. pylori* to reduce nitazoxanide was examined. For this, the *H. pylori* *rdxA* and *frxA* genes were expressed in *E. coli* by cloning into an overexpression vector pET29. The enzymes were purified using a nickel column and the substrate specificity for nitazoxanide and other compounds was determined spectrophotometrically in the presence of NADPH. The wavelength at which the reduction of each compound was measured is shown in Table 47. The results in Table 47 show that the nitroreductases encoded by the *rdxA* and *frxA* gene of *H. pylori* were capable of reducing nitazoxanide.

Cryptaz

Romark Laboratories

Table 47: Substrate specificity of RdxA and FrxA nitroreductases of *H. pylori*.

Substrate	Wavelength	Specific activity ($\mu\text{mol}/\text{min}/\text{mg protein}$) ^a	
		RdxA nitroreductase	FrxA nitroreductase
Metronidazole	320nm	5.13	<0.0002
NADPH (metronidazole) ^b	340nm	9.01	<0.0002
Nitazoxanide	412nm	13.4	22.2
Nitrofurazone	400nm	<0.0002	0.50
Furazolidone	400nm	<0.0002	1.50
Nitrofurantoin	420nm	<0.0002	2.01

^a Specific activities are calculated as the means for five assays of each of two independent batches of enzyme for FrxA and RdxA. The error in these assays is <15%.

^b NADPH oxidation was followed at 340 nm with metronidazole as the electron acceptor.

Overall, the results show that nitazoxanide can be reduced or activated by PFOR and the nitroreductases (RdxA and FrxA) of *H. pylori*.

In another study²¹, the mechanism of action of nitazoxanide was compared to that of metronidazole (another nitroimidazole) in *H. pylori*. Activated products of metronidazole are known to cause base substitutions (transversions and transition) in DNA resulting in an increase in papillation frequency. The ability of nitazoxanide to cause mutation was determined by a papillation assay using *Escherichia coli* tester strains carrying the *H. pylori rdxA* gene on plasmid pGS590. The strains carrying the *rdxA* gene express nitroreductase that confers susceptibility to metronidazole. Strains carrying pBluescript (vector without the *rdxA* gene) were used as controls. Dilution of overnight cultures of the different strains were plated on minimal glucose agar medium supplemented with phenyl- β -D-galactoside, ampicillin (100 $\mu\text{g}/\text{ml}$), 5-bromo-4-chloro-3-indolyl - β -D-galactoside (X-gal) and nitazoxanide or metronidazole (5 or 10 $\mu\text{g}/\text{ml}$) and incubated for 24 to 36 hours. The number of blue (β -galactosidase positive) papillae per total viable count was used to determine the papillation frequency. The results in Table 48 show that in the presence of nitazoxanide, the papillation frequency did not increase significantly in strains carrying the *rdxA* gene. However, metronidazole was shown to increase the papillation frequency in these strains (Table 49). The results suggest that although metronidazole and nitazoxanide are activated by RdxA, the mechanism of action of nitazoxanide is different from that of metronidazole. The study shows that nitazoxanide is not mutagenic in *E. coli* expressing the *H. pylori* RdxA nitroreductase. However, weak mutagenic effects were observed against the *Salmonella typhimurium* strain TA 100 using the Ames test [see NDA #20871 (N-000) pharmacologist review dated 24-4-96].

Cryptaz
Romark Laboratories

Table 48: Papillation frequency with Nitazoxanide.

Strain	Base Substitution In lacZ	Mutation Type	pBluescript			pGS950				
			Ntz (µg/ml)			Ntz (µg/ml)				
			0	5	10	0	5	10		
WT	GGG AAT GAG TCA GGC Glu									
CC101	GGG AAT TAG TCA GGC G	TV	32	29.8	30.1	53	72.6	115		
CC103	GGG AAT CAG TCA GGC G	TV	0.39	3.39	2.86	1.12	1.28	2.55		
CC104	GGG AAT GCG TCA GGC A	TV	35	19	11.5	100	90	51.4		
CC105	GGG AAT GTG TCA GGC A	TV	13.3	12.9	8.56	0.39	0.42	3.71		
CC106	GGG AAT AAG TCA GGC G	TS	0.86	0.77	6.48	124	50.9	76		

TV = transversions
TS = Transitions.

Table 49: Papillation frequency with Metronidazole.

Strain	Base Sub. lacZ	Metronidazole (µg/ml)									
		pBluescript				pGS950					
		0	5	10	15	0	5	10	15		
WT	GGG AAT GAG TCA GGC Glu										
CC101	GGG AAT TAG TCA GGC G	25	24	34	25	59	217	793	697		
CC103	GGG AAT CAG TCA GGC G	3.16	5.5	2.78	6.1	5.4	48	724	46,053		
CC104	GGG AAT GCG TCA GGC A	75	12	69	91	69	220	4,404	39,310		
CC105	GGG AAT GTG TCA GGC A	7	8.4	7	3.65	0.24	17.7	349	3,614		
CC106	GGG AAT AAG TCA GGC G	1.16	2.4	2.0	2.8	18.9	134	617	896		

In another experiment^{20, 21}, the ability of nitazoxanide and metronidazole to cause DNA damage/fragmentation were compared. For this, *E. coli* tester strain CC104 harboring the vector, pBluecript (pBSK) or pGS950 (carrying the *rdxA* gene) was incubated with different concentrations of nitazoxanide or metronidazole in minimal glucose medium at 37°C for 5 hours. Cells treated with hydrogen peroxide (20 mM) for 15 minutes were used as positive control. DNA extracted from the drug or hydrogen peroxide treated cells was subjected to alkaline gel electrophoresis, stained with ethidium bromide and visualized under ultraviolet light. The results in Figure 20 show that no smearing of DNA (indicating DNA damage) was observed in nitazoxanide treated *E. coli* cells carrying the *rdxA* gene (pGS950) or vector (pBSK). However,

DNA damage is observed in metronidazole treated *E.coli* cells carrying the *rdxA* gene on the plasmid pGS950 (Figure 21).

Figure 20: DNA fragmentation of *E.coli* strains challenged with nitazoxanide.






Figure 21: DNA fragmentation of *E.coli* strains challenged with metronidazole.



The results of the DNA fragmentation assay suggest that unlike metronidazole, nitazoxanide does not damage DNA in the presence of the *H. pylori rdxA* gene and the mechanism of action of the two drugs in *H. pylori* is different.

In addition to the effect of nitazoxanide on DNA damage, its ability to inhibit vacuolating toxin produced by *H. pylori* (possible cause of mucosal damage in infected individuals) was investigated²². For this, the bacterial cells were cultured in Brucella broth supplemented with 10% fetal calf serum with or without nitazoxanide at 37°C for 2 days. The culture supernatant was collected by centrifugation and concentrated 14-fold by ultrafiltration technique. Two-fold dilutions of the supernatants were added to a monolayer of HeLa cells in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum and 10 mM ammonium chloride. The intracellular vacuole development was observed under the microscope (magnification x 250) for a period of 24 hours. The vacuolating toxin activity was expressed as the reciprocal dilution of the culture supernatant showing cytotoxic effect ($\geq 50\%$ cells with vacuoles). The results for vacuolating toxin production (% of control) and bacterial growth in the presence of nitazoxanide are shown in Figure 22. The addition of nitazoxanide (1 µg/ml) reduced the bacterial growth by about 5% and the vacuolating toxin activity by 60%. At a higher concentration of nitazoxanide (5 µg/ml), both bacterial growth and vacuolating toxin activity were inhibited by > 80%.

Figure 22: Inhibition of vacuolating toxin production in *H. pylori* cultures by nitazoxanide. The bacterial growth was measured spectrophotometrically. The optical density of the control group at the end of culture was 0.502 ± 0.012 . The vacuolating activity of control cultures was 128 ± 32 (reciprocal dilution titer of culture supernatant which showed vacuolating effect). Each bar represents the mean \pm standard error for 3 experiments. * $p < 0.05$ compared with control group. ■ = bacterial growth; □ = vacuolating activity.



3. ACTIVITY *IN VITRO* AND *IN VIVO*:

The activity of Nitazoxanide was measured against selected protozoans (other than *Cryptosporidium* and *Giardia*), helminths, anaerobic and microaerophilic bacteria. These studies were conducted *in vitro* or in animals. A brief summary of the studies is as follows:

3.1. *Trichomonas vaginalis*:

3.1.1. *In vitro*:

The *in vitro* activity of nitazoxanide and tizoxanide was measured against 16 clinical isolates of *T. vaginalis* collected from vaginal secretions from women and prostatic/urine samples from men within the US²³. The trophozoites (10, 000/well) were incubated in the presence or absence of drug in modified Diamond's medium supplemented with 10% fetal calf serum, pH 5.9 under aerobic or anaerobic conditions for 46-50 hours at 37°C. The minimum lethal concentration (MLC) was the first dilution at which no motile trichomonads were observed.

The results in Table 50 show that all the isolates exhibited higher metronidazole MLC values under aerobic conditions compared to anaerobic conditions. It is also of note that the MLC values for nitazoxanide and tizoxanide were not altered by aerobic vs anaerobic conditions and were ≥ 8 -fold lower than metronidazole (Table 50). The actual parasite count was not included.

Table 50: Activity of nitazoxanide and tizoxanide against *T. vaginalis*.

	MLC ₉₀ (ug/ml)*		MLC ₅₀ (ug/ml)*	
	Anaerobic	Aerobic	Anaerobic	Aerobic
Metronidazole	25	>400	12.5	100
Nitazoxanide	3.2	6.4	1.6	1.6
Tizoxanide	0.8/1.6	1.6	0.4	0.8

* the results are based on the testing of 16 isolates.

In another study²⁴, the *in vitro* activity of nitazoxanide against clinical isolates of *T. vaginalis* was measured using Magara medium containing 5-10% human plasma (under anaerobic conditions). A 3-day old culture was used to determine the activity of nitazoxanide and metronidazole. The results were expressed as MLC or MIC (i.e., concentration required to completely inhibit the growth of the trophozoites). The concentration of the inoculum prepared for determining MLCs and MICs was different (MLCs: 150,000 to 600, 000 and MICs 100,000). However, the trophozoite count used per well for determining MLCs and MICs was not specified. The cultures were incubated at 37°C for 48 hours. The results in Table 51 show that the nitazoxanide and metronidazole MIC values to be comparable. However, the MLCs were about 4-fold higher for metronidazole compared to nitazoxanide. The number of isolates tested was not specified. The actual parasite count in the absence or presence of different concentrations of drug was not included.

Table 51: *In vitro* minimum lethal concentrations and minimum inhibitory concentrations.

Test Drug	Minimum Inhibitory Concentrations	Minimum Lethal Concentrations
Nitazoxanide	0.50-1.25 µg/ml	6 µg/ml
Metronidazole	0.25-1.00 µg/ml	25 µg/ml

3.1.2. *In vivo*:

The *in vivo* activity of nitazoxanide against *T. vaginalis* was measured in 4-week old Sprague Dawley female rats²⁴. The rats were castrated and permanent estrus maintained by subcutaneous administration of estradiol cyclopentenylpropionate. The sponsor has stated that *T. vaginalis* trophozoites were inoculated, however, the route of inoculation was not specified. Nevertheless, vaginal fluids were examined microscopically to confirm Trichomonas infection. Rats were treated for 6 days with either nitazoxanide or metronidazole by gavage or locally using vaginal suppositories (prepared in the lab) and the rats were followed for the presence of trophozoites in vaginal secretion.

The results were expressed as

- + numerous mobile trophozoites: treatment failures
- ± very few trophozoites with no or low mobility: treatment partially effective
- no trophozoites: effective treatment.

Cryptaz

Romark Laboratories

The results in Table 52 show that metronidazole was more effective than nitazoxanide when administered by gavage. However, the activity of nitazoxanide was similar to metronidazole when administered as an intravaginal suppository.

Table 52: Activity of nitazoxanide (a) oral solutions and (b) vaginal suppository against *T. vaginalis* in rats.

(a) oral solutions

Compound	Dose (mg/kg)	No. of Animals	1 st Control			2 nd Control			3 rd Control		
			+	±	-	+	±	-	+	±	-
Nitazoxanide	200	10	6	2	2	2	0	8	1	0	9
Metronidazole	20	9	0	3	6	3	2	4	2	0	7
Metronidazole	50	10	0	2	8	0	0	10	0	0	10
Untreated Controls	-	11	8	3	0	9	2	0	11	0	0

(b) vaginal suppositories

Compound	Dose (mg)	No. of Animals	1 st Control			2 nd Control			3 rd Control		
			+	±	-	+	±	-	+	±	-
Nitazoxanide	5	10	0	0	10	0	0	10	0	0	10
Metronidazole	5	10	0	0	10	0	0	10	0	0	10
Metronidazole	1	9	4	0	5	4	0	5	4	0	5
Untreated Controls	-	11	11	0	0	11	0	0	11	0	0

3.2. *Entamoeba histolytica*:

3.2.1. *In vitro*:

The activity of nitazoxanide and its metabolites against 5 strains of *Entamoeba histolytica* was examined *in vitro*¹⁵. Metronidazole was used as a positive control. Log phase culture of *E. histolytica* containing trophozoites (10^4) were incubated with two fold dilutions of the drugs in Diamond's TYI-S-33 complete medium supplemented with 10% inactivated bovine serum and 3% vitamin-tween 80 mixture at 35°C in 4% CO₂. The activity was measured by incorporation of ³H-thymidine and the cultures incubated for 24 additional hours. The drug concentration required for 50% inhibition of parasites (IC₅₀) was determined by regression analysis.

The results in Table 53 show that nitazoxanide and its metabolites, tizoxanide (TIZ) and tizoxanide glucuronide (TIZg) were active against 5 strains of *E. histolytica*. The activity of NTZ was similar to metronidazole (MTZ). The mean IC_{50s} for NTZ, TIZ, TIZg, and MTZ were $9.9 \pm 9.4 \mu\text{M}$ ($32.3 \pm 30.6 \mu\text{g/ml}$), $9.3 \pm 9.3 \mu\text{M}$ ($35.1 \pm 35.1 \mu\text{g/ml}$), $13.8 \pm 9.5 \mu\text{M}$ ($31.3 \pm 21.5 \mu\text{g/ml}$) and $14.6 \pm 30.4 \mu\text{M}$ ($85.3 \pm 68.9 \mu\text{g/ml}$), respectively.

Table 53: *In vitro* activity of nitazoxanide and its metabolites against *Entamoeba histolytica*.

Mean [SD] IC₅₀ in µM

Strain	MTZ	NTZ	TIZ	TIZg
IIM1:JMSS	11.21 [4.2]	8.16 [0.6]	9.01 [1.2]	25.86 [4.8]
NIH 200	9.52 [1.2]	4.85 [0.6]	7.39 [1.1]	7.31 [2.3]
H303	14.14 [6.4]	6.5 [1.3]	12.22 [2.2]	4.83 [0.5]
IULA:0593:2	28.49 [9.76]	15.55 [4.1]	7.01 [1.66]	13.3 [3.0]
IULA:1092:1	9.69 [0.5]	14.57 [0.7]	10.97 [2.0]	17.86 [7.7]
MEAN	14.61 [30.4]	9.93 [9.4]	9.32 [9.3]	13.83 [9.5]
t-test vs MTZ	-	NS	NS	NS

MTZ= metronidazole
 NTZ = nitazoxanide
 TIZ = tizoxanide
 TIZg = tizoxanide glucuronide
 NS = not studied

In another study²⁵, the *in vitro* activity of nitazoxanide against *Entamoeba histolytica* was measured by adding drug to either fresh or 24 hours old cultures of the parasites. The study has been reviewed previously [NDA# 20-871 (N-000), microbiology review dated 06-01-98]. The raw data were not provided in the report. It has been stated that nitazoxanide at concentrations of 0.5-1 µg/ml and 1-1.25 µg/ml inhibited fresh *Entamoeba histolytica*. However, inhibition of 24 hour old cultures required much higher concentrations of the drug (6 and 12.5 µg/ml, respectively). It was stated that this activity was similar to that observed with metronidazole, however, complete details of the experimental design and results were not provided for an independent evaluation.

3.2.2. In vivo:

No animal studies were conducted to examine the *in vivo* activity of nitazoxanide against *E. histolytica*. However, nitazoxanide (500 mg b.i.d for 3 days) was shown to be effective in patients with *E. histolytica* infections (for details see page 52)

3.3. Microsporidium:

3.3.1. In vitro:

Activity against *Encephalitozoon (Septata) intestinalis* was measured *in vitro* by infecting rabbit kidney cells (RK-13) with tissue culture derived microsporidia²⁶. This study is same as reviewed earlier [NDA# 20-871 (N-000), microbiology review dated 06-01-98]. The results show that nitazoxanide and desacetyl nitazoxanide at a concentration of 1 µg/ml resulted in about 70% parasite inhibition with minimal toxicity. Higher concentrations of the drug were toxic to the mammalian cells. Similar results were observed against *Vittaforma corneae*.

3.3.2. In vivo:

Studies examining the *in vivo* activity of nitazoxanide against *Microsporidium* were not conducted.

3.4. Trematodes (*Fasciola hepatica* and *Fasciola gigantica*):

3.4.1. *In vitro*:

The mature flukes (obtained from infected calves) in RPMI-Rabbit serum with 2% rabbit blood plus 100 ppm penicillin and 100 ppm streptomycin were exposed *in vitro* to different concentrations of nitazoxanide or its metabolite²⁷. Presence of the nitazoxanide at a concentration of ≥ 10 $\mu\text{g/ml}$ was shown to decrease motility and to cause more death of the worms as compared to control cultures. A higher concentration of deacetyl-nitazoxanide (≥ 25 $\mu\text{g/ml}$) was required for similar activity.

3.4.2. *In vivo*:

The activity of nitazoxanide against *Fasciola gigantica* was tested in rabbits²⁸. In one experiment, rabbits were infected orally with 35-40 encysted metacercariae (placed in a lettuce leaf). It was stated that immature fluke stages were observed in rabbits at 4 weeks post-infection. Four weeks after infection, nitazoxanide (35 mg/kg or 75 mg/kg) was administered by the oral route for 7 days. Untreated animals were used as controls. At the end of treatment, the number of flukes in the liver tissue and washings of the abdominal cavity and visceral surface was determined. The raw data were not included in the submission. The sponsor has stated that 40-60% reduction in immature flukes was observed in nitazoxanide treated animals.

In another experiment, metacercariae (10-15) were used to infect rabbits and the treatment was initiated 10 weeks post-infection. Treatment with nitazoxanide was at the same dose as described above. It was stated that mature fluke stages were observed at 10 weeks post-infection. Here again, the raw data were not included. The sponsor has stated that no flukes were observed in nitazoxanide treated animals compared to untreated controls. Based on these results the sponsor has concluded that nitazoxanide at 35 mg/kg or 75 mg/kg dose for 7 days was effective against mature flukes.

3.5. Nematodes and Cestodes:

3.5.1. *In vitro*:

No studies examining the *in vitro* activity of nitazoxanide against nematodes and cestodes were included in the submission.

3.5.2. *In vivo*:

The activity of nitazoxanide against helminthic infections was examined in dogs^{29,30}. This study has been reviewed earlier [NDA# 20-871 (N-000), microbiology review dated 06-01-98]. Studies were conducted in 15 dogs experimentally infected with *Taenia pisiformis* and 13 farm dogs naturally infected with nematodes (round worms, hookworms and whipworms) or a cestode (*Dipylidium caninum*). For the experimental infection model, dogs were administered 14 to 20 viable cysts of *Taenia pisiformis* by the oral route and treatment with nitazoxanide (75 mg/kg) was administered as a single dose at 6 (group 1) or 8 weeks (group 2) post-infection (the route of

Cryptaz
Romark Laboratories

drug administration was not specified). At these times, immature and mature worms, respectively, would be present in the dogs. The fecal samples were examined at different time intervals (1, 8, 12, 24, and 48 hours) after drug administration for the presence of strobila with the naked eye and also concentrated by filtering through a sieve. No untreated or vehicle treated group was used for comparison. At 19 and 4 days post-administration of a single dose of nitazoxanide for the first and second group respectively, the dogs were necropsied and the gastro-intestinal tract was examined for the presence of *Taenia* species. The results in Table 54 show the continued presence of parasite in fecal samples up to a period of 24 hours post-therapy in both groups. Although the sponsor has stated that the dogs were examined for a period of up to 48 hours post treatment, only results obtained between 0-9 and 10-24 hours were shown. At necropsy on day 4 or 19, however, no parasites were observed in the intestine. Nevertheless, in the absence of untreated controls it is difficult to evaluate the activity of the drug because infections with the parasite can be cured up to certain point in immunocompetent hosts. Also, no baseline measurement(s), before initiating treatment, were performed.

Group No	Dog No	Sex	Hours Post-treatment		Number of Worms Recovered at Necropsy	Day of Sacrifice
			0-9	10-24		
1	N01	F	2	0	0	DAY 19
	N04	M	3	1	0	
	N05	F	0	0	0	
	N06	M	4	0	0	
	N10	F	0	0	0	
	N14	M	1	3	0	
	N15	M	0	2	0	
2	N03	F	2	1	0	DAY 4
	N02	F	0	0	0	
	N05	F	3	0	0	
	N07	F	2	2	0	
	N09	M	3	1	0	
	N18	M	3	0	0	
	M09	M	0	0	0	
	M16	M	3	1	0	

Table 54: Activity of nitazoxanide against *Taenia pisiformis*

In 13 naturally infected dogs, 3 different dosage regimens of nitazoxanide were administered by oral route (mixed with meat) as shown in Table 55.

Table 55: Activity of nitazoxanide against helminths.

Group (Number)	Drug administration		Activity against parasites examined*			
	Dose (mg/kg)	Days	Dc	Tv	Us	Tc
3 (3)	100, 100 & 200	1, 2 & 8	+	±	±	-
4 (4)	100, 100 & 250	1, 2 & 8	+	±	-	-
5 (3)	150 & 150	1 & 2	+	+	±/-	-
6 (3)	200 & 200	1 & 2	+	-	-	-

Dc = *Dipylidium caninum*
 Tv = *Trichuris vulpis*
 Us = *Uncinaria stenocephala*
 Tc = *Toxocara canis*

Cryptaz

Romark Laboratories

The animals were followed for toxicity and the presence of parasites in the fecal samples at different intervals. The fecal samples were examined with the naked eye for the presence of strobila and also by passing through a sieve. The dogs in groups 5 and 6 were necropsied 24 hours after discontinuation of treatment and 48 hours later for those in groups 3 and 4 and the intestine was processed to determine if parasites were present. The sponsor has identified the parasites recovered and their number at different time intervals and has concluded that nitazoxanide at a dose of ≥ 100 mg/kg was effective in eliminating the cestode *Dipylidium caninum* since no parasites were observed beyond 24 hours in fecal samples nor in the small intestine at necropsy. The sponsor has also stated that in a previous study administration of 75 mg/kg of nitazoxanide was not effective against this infection. However, the details of these results were not included for review.

Drug activity against 3 species of nematodes, based on examination of the intestine at necropsy, is summarized in Table 55 above. Baseline measurements (that is the number of parasites present in the fecal samples before initiation of treatment) were not performed. Unfortunately, due to the absence of untreated controls in the experiment it is difficult to interpret these data.

In another study²⁸, cats naturally infected with *Taenia taeniaeformis* were used to examine the activity of nitazoxanide. Nitazoxanide was administered as a single oral dose of 100 mg/kg. The sponsor has stated that the cestodes were eliminated between 8 hours and 3 days post-treatment. The raw data were not included for an independent evaluation.

In another experiment, studies were conducted using sheep naturally infected with *Moniezia expansa*, *Thysanieza ovilla*, *Stilesia globipunctata* and *Avitellina centripunctata*. The sheep were administered nitazoxanide (200 mg/kg or 400 mg/kg) as a single dose by the oral route. The sponsor has stated that no tapeworms were observed in the animals at necropsy 4-5 days after treatment. Here again, the raw data were not included for an independent evaluation.

In another study²⁵, the activity of nitazoxanide was measured against *Syphacia obvelata* (a nematode), and *Hymenolepis nana* (a cestode) *in vivo*. This study has been reviewed previously [NDA# 20-871 (N-000), microbiology review dated 06-01-98]. Mice were infected with *Syphacia obvelata* by placing uninfected mice with infected mice in the same cage for 5 days. Treatment with nitazoxanide (200 mg/kg) or the vehicle was initiated on day 8 for 4 days by the oral route. Two days after discontinuation of treatment, the mice were necropsied and the cecum was examined for the presence of adult worms (≥ 0.5 mm in length). The sponsor has stated that all the mice treated with the vehicle were parasitized, whereas no parasites were observed in 60% of the treated mice. The remaining 40% of the mice treated with nitazoxanide were partly free of worms. The raw data demonstrating the number of parasites recovered were not provided for an independent evaluation and the effect on other stages of the parasite was not evaluated.

In order to measure the activity of nitazoxanide against *Hymenolepis nana*, mice were infected with the egg stage of the parasite and the establishment of infection confirmed by the excretion of eggs in the feces on days 20 to 25 after infection. Mice were then treated with either nitazoxanide (200 mg/kg) or the vehicle for 4 days by the oral route and examined for the presence of worms in the small intestine. The sponsor has stated that mice treated with nitazoxanide were completely deparasitized, whereas untreated mice were completely

Cryptaz

Romark Laboratories

parasitized. The raw data were not provided for an independent evaluation. In another experiment conducted as described above, different doses of the drug were administered and the activity of the drug compared to that of niclosamide. The results show that a dose of ≥ 50 mg/kg for 4 days was effective in clearing the worms from the small intestine.

3.6. Bacteria:

3.6.1. *In vitro*:

The activity of nitazoxanide against 241 anaerobic bacteria and 9 aerobic bacteria using clinical isolates and 4 reference ATCC control strains (aerobic and anaerobic) was examined by the NCCLS method^{31,32}. This study has been reviewed previously [NDA# 20-871 (N-000), microbiology review dated 06-01-98]. The results show that the anaerobic strains that are susceptible to metronidazole were also susceptible to nitazoxanide. Activity of the metabolite of nitazoxanide was one fold less than that of the parent compound. Aerobic organisms were not susceptible to nitazoxanide under aerobic conditions. *Staphylococcus aureus* (34 clinical isolates) showed about 8 fold lower MIC values under anaerobic conditions as compared to aerobic conditions. Also, about 8 fold lower MIC values were observed against 2 *Staphylococcus epidermidis* strains under anaerobic compared to aerobic conditions. Break-points for susceptibility were not established.

Activity of nitazoxanide was measured against 103 strains of *Helicobacter pylori* isolated from patients with duodenal ulcer or non-ulcer dyspepsia in France³³. The MICs were determined by the agar dilution method using Wilkins Chalgreen agar supplemented with 10% sheep blood and polyvitex at pH 6.5. The MIC values indicate that the activity of nitazoxanide and tizoxanide may be similar to that of metronidazole.

The activity of nitazoxanide against *Clostridium difficile* was examined *in vitro*^{34,35}. The *in vitro* susceptibility of 15 toxigenic strains of *C. difficile* to nitazoxanide was measured using Wilkins-Chalgreen broth by the microbroth dilution method. Vancomycin and metronidazole were used as comparators. Nitazoxanide was solubilized in DMSO while vancomycin and metronidazole was solubilized in saline or medium. All drugs were then diluted in medium. The cultures were incubated in the presence of different dilution of the drugs at 37°C for 48 hours under anaerobic conditions. The minimum inhibitory concentration (MIC) defined as the lowest concentration of the drug that completely inhibited bacterial growth was determined. The minimum bactericidal concentration (MBC) defined as the concentration that killed 99.9% of the bacteria was also determined by subculturing aliquots of cultures onto Wilkins-Chalgreen agar at the end of the 48 hour incubation. Additionally, the stability of nitazoxanide in the presence of 5% hamster cecal content (filtered through a 0.45 μ m filter) was determined. The results in Table 56 show that the activity of nitazoxanide was similar to metronidazole and vancomycin. However, the MICs required to inhibit 90% of the strains (MIC₉₀) was 64 fold higher in the presence of 5% hamster cecal content than in its absence. The activity of metronidazole and vancomycin were not significantly altered in the presence of 5% hamster cecal content. The mean MBCs \pm standard deviation for nitazoxanide in the absence and presence of 5% hamster cecal content against *C. difficile* were 0.48 ± 0.47 μ g/ml and 13.6 ± 12.7 μ g/ml, respectively. The break-points for susceptibility have not been established.

Table 56: MIC of antimicrobial agents for 15 toxigenic *C. difficile* strains.

Antimicrobial agent:	MIC (µg/ml)		
	MIC ₅₀	MIC ₉₀	Range
NTZ	0.25	0.50	0.13-1
Metronidazole	0.25	0.50	0.13-0.50
Vancomycin	0.50	0.50	0.13-1.0
NTZ in 5% cecal contents	4	32	0.50-32
Metronidazole in 5% cecal contents	0.25	0.50	0.13-1
Vancomycin in 5% cecal contents	1	1	0.50-1

MIC₅₀ = MIC for inhibition of 50% strains

MIC₉₀ = MIC for inhibition of 90% strains.

3.6.2. *In vivo*:

The ability of nitazoxanide to prevent clindamycin-induced ileocecolitis was examined in hamsters^{34,35}. For this hamsters were administered clindamycin (3 mg/100 gram body weight) orally and inoculated with 10⁵ cfu of a *C. difficile* strain 24 hours later. One day post infection, nitazoxanide (3, 7.5 or 15 mg/100 gram body weight) was administered orally once a day for 6 days. The sponsor has stated that the control animals died within 72 hours of infection. All hamsters treated with nitazoxanide died within two week of discontinuation of treatment.

D. Effect of nitazoxanide on the inflammatory responses:

Nitazoxanide contains a salicylic acid moiety that is also present in the structures of non-steroidal anti-inflammatory compounds such as aspirin. Therefore, the drug may have the potential to exhibit anti-inflammatory activity. The anti-inflammatory effect of nonsteroidal compounds has been shown to be due to inhibition of cytokines, chemokines, superoxide radicals, nitric oxide and other mediators produced by neutrophils and macrophages. These activities are important for protection against infection by microorganisms. Thus, modulation of these activities may impact the progression of diarrhea due to *Cryptosporidium* or *Giardia*.

The effect of nitazoxanide on inflammatory response was examined using unstimulated and cytokine stimulated human intestinal epithelial (HCT-8) cells³⁶. For this, the monolayers of HCT-8 cells in DMEM supplemented with 10% heat inactivated fetal calf serum (FCS), 1% non-essential amino acids, antibiotics, and 2 mM L-glutamine were stimulated by incubating in the presence of interferon gamma (IFN-γ, 1 ng/ml), transforming growth factor-alpha (TNF-α; 20 ng/ml), and interleukin-1β (IL-1β; 10 ng/ml) for 2 or 6 hours at 37°C in 5% CO₂. Nitazoxanide (5 ng/ml) was added and the incubation continued for additional 24 hours. RNA was obtained from the cells at different time points (3, 6 and 24 hours). The mRNA level of interferon inducible protein-10 (IP-10), interleukin-8 (IL-8) and inducible nitric oxide synthase (iNOS) was measured by reverse transcription-polymerase chain reaction (RT-PCR). The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as a control. The primers used for the PCR reaction are shown in Table 57. The PCR products were quantified using a densitometer after autoradiography.

Table 57: Oligonucleotide primers for detection of IP-10, IL-8, iNOS and GAPDH.

Gene	Oligonucleotide primer sequences 5'- 3'(up/down)	Product size (bp)
IP-10	AGTGGCATTCAAGGAGTACC/ ATCCTTGGGAAGCACTGCATC	288
IL-8	TCTGATGGAAGAGAGCTCTG/ GATATTCTCTGGCCCTTGG	413
iNOS	TTCAGGTACGCTGTGTTGG/ GGGGATCTGAATGTGCTGTT	231
GAPDH	AATCCCATCACCATCTTCCA/ TGTGGTCATGAGTCTTCCA	318

The results show that nitazoxanide (5 ng/ml) did not alter the levels of IP-10, IL-8 and iNOS mRNA in HCT-8 cells stimulated by cytokines for 2 hours (Figure 23) or 6 hours (Figure 24). Exposure of unstimulated HCT-8 cells to nitazoxanide increased the IL-8 mRNA levels by 2 fold (Figure 24)




Figure 23: Kinetics of iNOS, IL-8 and IP-10 mRNA response in HCT-8 cells exposed to cytokines in the absence or presence of nitazoxanide. The results (% gapdh) are expressed as ratio of level of target gene product to control gene (gapdh) product (one experiment).

iNOS = inducible nitric oxide synthase.
 IL-8 = interleukin-8
 IP-10 = interferon inducible protein 10




Figure 24: Level of iNOS, IL-8 and IP-10 mRNA in HCT-8 cells exposed to cytokines in the absence or presence of nitazoxanide. The results (% gapdh) are expressed as mean ratio of level of target gene product to control gene (gapdh) product (three experiments). Bars represent one SD from the mean

iNOS = inducible nitric oxide synthase.
 IL-8 = interleukin-8
 IP-10 = interferon inducible protein 10

In another experiment, the effect of nitazoxanide on the amount of nitrites and nitrates (NO) formed by the metabolism of nitric oxide in unstimulated and cytokine stimulated HCT-8 cells was measured. The HCT-8 cells were stimulated with cytokines as described above for 6 hours. The cells were then exposed to nitazoxanide (5 ng/ml) for 4 hours. The concentrations of nitrites and nitrates in culture supernatants were determined spectrophotometrically using nitrate reductase and Griess reagent kit. The results in Figure 25 show a 3-fold reduction in the amount of nitrites and nitrates produced by HCT-8 cells stimulated with cytokines and exposed to nitazoxanide.




Figure 25: Effect of 6 hour cytokine and/or 4 hour nitazoxanide exposure on total nitrite and nitrate (NO) production. Values are means \pm SD of three experiments.

In another experiment, the concentration of IL-8 in the culture supernatants of unstimulated and cytokine stimulated HCT-8 cells in the presence or absence of nitazoxanide was examined. The experimental design was same as described above. The results in Figure 26 show that

nitazoxanide at a concentration of 5 ng/ml did not alter the concentration of IL-8 in unstimulated or stimulated HCT-8 cells




Figure 26: Effect of 6 hour cytokine and/or 4 hour nitazoxanide exposure on IL-8 production. Values are means \pm SD of three experiments. The IL-8 levels were determined using IL-8 specific monoclonal antibody by an enzyme-linked immunosorbent assay (ELISA).

Overall, the results show that nitazoxanide at a concentration of 5 ng/ml did not alter the mRNA levels of iNOS, IL-8 and IP-10 in cytokine (IL-1 β , INF- γ , and TNF- α) stimulated HCT-8 cells *in vitro*. A 2-fold increase in the mRNA level of IL-8 was observed in unstimulated HCT-8 cells exposed to nitazoxanide. However, nitazoxanide did not alter the production of IL-8 in unstimulated or cytokine stimulated HCT-8 cells. Nitazoxanide was also shown to decrease the production of nitric oxide in cytokine stimulated HCT-8 cells. Higher concentrations of nitazoxanide were not tested in these experiments. Additionally, *C. parvum* infected HCT-8 cells were not used. It is unclear if nitazoxanide will have similar effects on infected versus uninfected cells *in vivo*.

The target enzymes for nonsteroidal anti-inflammatory compounds are cyclooxygenases that are involved in the production of prostaglandins (PGE₂ and PGH). The effect of nitazoxanide on cyclooxygenases, PGE₂ secretion, and other inflammatory responses in the rat carrageenan-induced paw edema model was examined (for details see pharmacologist's review). Nitazoxanide and tizoxanide were shown to inhibit cyclooxygenase (Cox-1 and Cox-2) and the production of PGE₂. Using the rat carrageenan-induced paw edema model, nitazoxanide (500 mg/kg) was shown to be less effective (29%) than the nonsteroidal anti-inflammatory agent, indomethacin (46%), in reducing the edema.

The above studies suggest that nitazoxanide has some anti-inflammatory activity and may modulate the host immune response. However, in studies examining the efficacy of nitazoxanide in the treatment of diarrhea due to *Cryptosporidium* or *Giardia*, a correlation of parasitological and/or clinical outcome with immune/inflammatory responses was not examined.

E. Drug Resistance:

A potential for development of resistance by *C. parvum* and *G. lamblia* to nitazoxanide was not examined.

F. CONCLUSIONS:


The sponsor is seeking an approval for use of nitazoxanide in the treatment of diarrhea due to *C. parvum* and *G. lamblia*

Mechanism of Action:

The survival of protozoa that lack mitochondria and microaerophilic bacteria under anaerobic conditions depend on the presence of the enzyme pyruvate:ferredoxin oxidoreductase (PFOR) which plays an important role in glucose metabolism (Figure 27). PFOR catalyzes the conversion of pyruvate to acetylCoA and CO₂ using ferredoxin as an electron acceptor *in vivo*. Benzyl viologen and methyl viologen have been shown to act as alternate electron acceptors *in vitro*.

Studies show that nitazoxanide can also act as an electron acceptor and is reduced by the PFOR enzyme from protozoa (*G. lamblia*, *T. vaginalis*, and *E. histolytica*), and anaerobic bacteria (*C. difficile*, *C. perfringens*, and *H. pylori*). It is possible that the reduction of nitazoxanide by PFOR can lead to generation of a toxic radical. Although, the *C. parvum* genome analysis revealed the presence of a PFOR like enzyme with 31-51% sequence similarity to PFOR sequences from other protozoa and bacteria, the ability of this enzyme to reduce/activate nitazoxanide was not investigated.

Figure 27: Activation of nitazoxanide by pyruvate:ferredoxin oxidoreductase (PFOR) enzyme from protozoa.



It is possible that nitazoxanide may exhibit its effects through other pathways. For example, two other enzymes, the RdxA and FrxA nitroreductases of *H. pylori* were shown to activate the drug. Nitazoxanide did not induce mutations and damage DNA of *Escherichia coli* expressing the *H. pylori rdxA* gene product.

Overall, the studies show that nitazoxanide acts as an electron acceptor (Table 57). The ability of nitazoxanide to inhibit the PFOR enzyme was not measured. The precise mechanism by which nitazoxanide exhibits activity against *C. parvum* or *G. lamblia* is not known.

Cryptaz

Romark Laboratories

Table 57: Summary of the studies examining mechanism of action of nitazoxanide in protozoa and bacteria.

Organism	Activity of enzyme PFOR	Nitazoxanide as electron acceptor for PFOR	Mutation frequency	DNA damage	Other nitroreductase activating nitazoxanide	Anti-vacuolating activity of nitazoxanide	Other	Genome Sequence similarity to the <i>C. parvum</i> PFOR sequence (%)
<i>C. parvum</i>	ND	ND	ND	ND	ND	ND	Genome analysis	
<i>G. lamblia</i>	+	yes	ND	ND	ND	ND	Genome analysis	31%
<i>E. histolytica</i>	+	yes	ND	ND	ND	ND	Genome analysis	49%
<i>T. vaginalis</i>	+	yes	ND	ND	ND	ND	Genome analysis	43%
<i>Cl. pasteurianum</i>	ND	ND	ND	ND	ND	ND	Genome analysis	51%
<i>Cl. perfringens</i>	+	yes	ND	ND	ND	ND	ND	
<i>Cl. difficile</i>	+	yes	ND	ND	ND	ND	ND	
<i>H. pylori</i>	+	yes	ND	ND	RdxAFrxA	+	ND	
<i>H. pylori rdxA</i>	ND	ND	ND	ND	ND	ND	ND	
<i>E. coli + H. pylori rdxA</i>	ND	ND	No mutation	absent	ND	ND	Susceptibility to nitazoxanide in the presence of RdxA nitroreductase	

ND = not done

+ = present

Activity *in vitro* and *in vivo*:***C. parvum*:**

The activity of nitazoxanide against *C. parvum* was measured *in vitro* and *in vivo*. *In vitro* activity was determined using different cell lines such as MDBK-F5D2, HCT-8 or A-549 cells infected with oocysts or sporozoites. However, due to variation in methodology (such as time of initial exposure to drug, incubations time, methods used for quantitative analysis) comparison of results is difficult.

MDBK cells infected with the oocyst stage and incubated with nitazoxanide (1 µg/ml) for 48 hours decreased the number of parasites by 29 to 94% with minimal toxicity (≤ 8 %) to the mammalian cells. The activity of the metabolite (tizoxanide) appears to be similar to nitazoxanide when tested under similar experimental conditions. The activity of the other metabolite, tizoxanide glucuronide, was not measured.

In another study, using A-549 cells infected with sporozoites, a higher concentration of nitazoxanide (8 µg/ml) was required to inhibit parasite growth by 50% at 48 hours. The toxicity to A-549 cells was ≤ 11% at this concentration. In a single experiment, a combination of nitazoxanide with azithromycin or rifabutin was shown to be more active against *C. parvum* than nitazoxanide alone.

In another study, the activity of nitazoxanide and its metabolites was examined using HCT-8 cells infected with sporozoites using immunofluorescence and enzyme immuno assays. Exposure of 2-hour old cultures to nitazoxanide (10 µg/ml) for 4 or 46 hours reduced the parasite counts by ≥ 88% using the immunofluorescence assay with 14% toxicity to the HCT-8 feeder cells. Similar observation was made when older cultures (18-hour old) were exposed to the drug for 4 hours. The inhibition of parasite in older cultures (18-hour old) exposed to nitazoxanide

Cryptaz

Romark Laboratories

was lower (30%) using enzyme immunoassay compared to the immunofluorescence assay. However, the inhibition of parasite in younger cultures (2-hour old) exposed to nitazoxanide was comparable using the two methods. At a concentration of 10 µg/ml, the metabolites (tizoxanide and tizoxanide glucuronide) caused fragilation and peeling of the HCT-8 cell. The sponsor has stated that asexual stages and sexual stages were observed in cultures at 2-6 hours, and 18-22 hours, respectively. The antiserum used in the above assays cross-reacted with all stages of the parasite including oocysts. However, photographs depicting the different stages of the parasite at 2 hours and 18 hours were not taken. In another study using a different cell line (A-549), meront and gamont stages were observed 48 hours after infection of cells with *C. parvum* sporozoites. In the absence of complete information, the effect of the drug on the different stages is unclear. In a single experiment, nitazoxanide (10 µg/ml) was shown to reduce the number of zygotes in *C. parvum* infected HCT-8 cells in electron microscopic sections. However, macrogametes were observed in nitazoxanide treated cultures but not in controls. The number of parasites reported is too small to draw conclusions on the effect of the drug on the different stages. Also, no comparator was used in these studies.

The *in vivo* studies examining activity of nitazoxanide were conducted in 4 different animal models (rodents and gnotobiotic piglets). It is of note that rodents infected with *C. parvum* do not exhibit diarrhea whereas gnotobiotic piglets do. Studies in **suckling mice** show that nitazoxanide (1.3 mg b.i.d. for 7 days) was effective in reducing the oocyst count detected by the rectal swabs compared to untreated control animals. Such an effect was observed up to 7 days after discontinuation of treatment. Residual parasitic load was not examined in the tissues and paromomycin was not used for comparison of activity. In another study using a powder and an injectible formulation of nitazoxanide (100 mg/day), the powder formulation showed about 50% reduction in mucosal oocysts counts while the injectible formulation showed a 75% reduction in mucosal oocyst counts at the end of 5 days of treatment. This may be due to poor bioavailability of the powder formulation. Paromomycin (50 mg/day for 5 days) was more effective than nitazoxanide in reducing mucosal oocyst counts. The effect of nitazoxanide on shedding of oocysts in stool was not examined in this study.

In the **scid mice** model, two experiments were conducted. In one experiment treatment with nitazoxanide (100 mg/kg) decreased oocyst shedding in the stool samples compared to vehicle treated mice. Parasitic load in the mucosa was also decreased when measured 5 days after discontinuation of treatment. In the second experiment, however, nitazoxanide did not show any activity. Paromomycin was active in both experiments. Reasons for the observed difference in the activity of nitazoxanide in the 2 experiments are unknown. In another experiment performed in scid mice, desacetyl nitazoxanide (tizoxanide) failed to show any activity. While nitazoxanide was not used for comparison in this study, paromomycin was shown to be active.

Studies in **immunosuppressed rats** show that the oocysts counts decreased in control animals over a period of 21 days post-infection. A 2-fold decrease in oocyst counts was observed during treatment with 100 or 200 mg nitazoxanide. The activity of paromomycin was similar to nitazoxanide while sinefungin was more effective than nitazoxanide during treatment. However, no difference in the oocyst counts was observed in the drug treated and control animals after discontinuation of treatment. A 2 to 4-fold decrease in mucosal infection was observed in

Cryptaz

Romark Laboratories

nitazoxanide treated animals compared to untreated control animals. Paromomycin and sinefingir were not used as comparators in this study.

In a study in **gnotobiotic piglets** a trend towards a decrease in oocyst scores from days 9 to 13 in nitazoxanide-treated animals was observed. Due to a small number of animals studied and the variability in the oocyst score, it is not clear whether the differences observed between the treated and untreated groups were significant. The incidence of diarrhea was same in all the untreated and nitazoxanide treated animals. In these studies paromomycin was more effective than nitazoxanide in reducing oocyst numbers, mucosal infection scores and in resolution of diarrhea. In another study, no reduction in oocyst counts was observed in animals treated with nitazoxanide. Similar experimental designs and drug doses were used in the two studies. The reason(s) for this discrepancy are not known.

The development of resistance by *C. parvum* to nitazoxanide was not examined.

Immunocompetent patients (children and adults) with cryptosporidial diarrhea, 40% (24/60) of patients treated with nitazoxanide showed absence of oocysts in stool samples at 6-23 days after initiation of therapy compared to 7% (5/67) patients in the placebo group. The parasitological evaluations in these studies were limited to microscopic examination of small amount of stool after acid fast or auramine-phenol staining. Concentrated stool samples for the detection of parasites were not used consistently across studies and the testing of stool samples using more sensitive techniques such as immunofluorescence was performed only in 9 patients. Examination of 2 or more stool samples by 2 different methods (ZNN and IFA) appears to provide a better measure of oocyst levels in the stool. There appears to be no correlation between clinical and parasitological response except in children 4-11 years of age. In HIV positive children, nitazoxanide at the dose of 100 mg b.i.d. for 3 days was ineffective in the treatment of cryptosporidial diarrhea.

G. lamblia:

The studies examining the *in vitro* and *in vivo* activity of nitazoxanide against *G. lamblia* were limited. One study examined the *in vitro* activity of nitazoxanide and its metabolites against 6 strains of *G. lamblia* by incorporation of radiolabeled thymidine. The nitazoxanide IC₅₀ values against the 6 strains ranged between 3.5 and 25.4 µg/ml and were 2 to 5 fold lower than the metronidazole IC₅₀ values. The activity of tizoxanide was similar to nitazoxanide, however, tizoxanide glucuronide was less active (IC₅₀ values 2 to 30-fold higher) than nitazoxanide. Although, the test measures multiplication of trophozoites, it is possible that the trophozoites are still viable. Motility or other viability tests were not performed. In another study, using a different adherence assay and Caco-2 cells as feeder layer, the IC₅₀ values of nitazoxanide against 3 clinical isolates were between 61 and 74 µg/ml. The activity of tizoxanide was similar to nitazoxanide (IC₅₀ values 50 to 82 µg/ml). The toxicity of nitazoxanide or tizoxanide to Caco-2 cells was not examined. The IC₅₀ values based on the adherence assay were 3 to 18-fold higher than that obtained using incorporation of ³H-thymidine. There are no established methods for susceptibility testing of *Giardia*. In the absence of toxicity data and standardized methods, the usefulness of the IC₅₀ values in predicting *in vivo* activity is not known.

Cryptaz

Romark Laboratories

In neonatal mice infected with the _____ strain of *G. lamblia*, nitazoxanide (100 and 200 mg/kg) showed a decrease in trophozoite counts in the intestinal tissue at 48 hours post-treatment. The variability in the trophozoite counts in the untreated control animals was very large (14 - 330). The *in vivo* activity of nitazoxanide against other strains of *G. lamblia* was not tested.

Nitazoxanide was shown to be effective in the treatment of 6/8 immunocompetent adults with giardiasis compared to the placebo (0/10). In immunocompetent children, nitazoxanide was shown to be as effective as metronidazole in the treatment of giardiasis. Examination of 2 or more post-treatment samples was useful in the detection of cysts after drug treatment. The concentration and IFA methods appear to be more sensitive in detection of cysts in stool samples when the numbers were low.

Studies examining the development of resistance by *G. lamblia* to nitazoxanide were not performed.

Overall, nitazoxanide and its metabolite, tizoxanide were effective in inhibiting of the growth of sporozoites and oocysts of *C. parvum* and trophozoites of *G. lamblia* (Table 59). The metabolite, tizoxanide glucuronide, was less effective in inhibiting the growth of sporozoites of *C. parvum*, however, its activity against the oocyst stage was not tested. Tizoxanide glucuronide was also less effective than nitazoxanide or tizoxanide against the trophozoites of *G. lamblia*.

Table 59: Effect of nitazoxanide and its metabolites on the growth of *C. parvum* and *G. lamblia*.

Drug	<i>C. parvum</i>		<i>G. lamblia</i>
	Sporozoite	Oocyst	Trophozoite
Nitazoxanide (NTZ)	Inhibition	Inhibition	Inhibition
Tizoxanide (TZ)	Inhibition but cytotoxic	Inhibition	Inhibition
Tizoxanide glucuronide (TZg)	Inhibition but cytotoxic	Not tested	Inhibition (2-30 fold lower than NTZ and TZ)

Other microorganisms:

The activity of nitazoxanide against protozoans (other than *Cryptosporidium* and *Giardia*), helminths and bacteria was measured. Nitazoxanide was shown to be active against the trophozoites of *E. histolytica in vitro* and effective in the treatment of patients with amebiasis. The information provided in the study reports on other protozoa, helminths and bacteria is very limited. Since the broad spectrum anti-bacterial and anti-parasitic indications are not under consideration at the present time no attempts were made to obtain additional information from the sponsor about these studies.

Effect of nitazoxanide on inflammatory and immune response:

In vitro, nitazoxanide at a concentration of 5 ng/ml did not have an effect on the mRNA levels of inducible nitric oxide synthase, interleukin-8 (IL-8) and interferon inducible protein 10 in cytokine stimulated human intestinal epithelial (HCT-8) cells. However, the drug inhibited the


Cryptaz

Romark Laboratories

production of nitric oxide in these cells. A 2-fold increase in IL-8 mRNA levels was observed in unstimulated HCT-8 cells exposed to nitazoxanide. However, the production of IL-8 was not altered in unstimulated and stimulated HCT-8 cells in the presence of nitazoxanide. It is unclear whether nitazoxanide will have a similar effect on these immune modulators *in vivo*. Like other anti-inflammatory compounds, nitazoxanide inhibited the activity of cyclooxygenases and production of prostaglandins *in vitro*.

In vivo, nitazoxanide reduced carrageenan induced paw edema in rats by 29% compared to 46% in animals treated with indomethacin. The effect of nitazoxanide on immune function in patients with cryptosporidial diarrhea or giardiasis has not been examined.

G. THE LABEL:



4 Page(s) Withheld

 Trade Secret / Confidential

 / Draft Labeling

 Deliberative Process



H. RECOMMENDATIONS:

This NDA is approvable with respect to Microbiology pending an accepted version of the label. The following recommendation should be considered for future drug development.

1. For future clinical studies, please consider performing parasitological evaluations using multiple stool samples at different time points such as, at baseline, end of therapy and 3-4 weeks post therapy. Concentration techniques for stool samples in combination with more sensitive immunofluorescence or enzymeimmunoassays should be used for detection of the parasite. Attempts should be made to correlate parasitologic outcome with clinical outcome.

Kalavati Suvama
Microbiologist, HFD-590

Cryptaz

Romark Laboratories

CONCURRENCES:

HFD-590/Deputy Dir. _____ Signature _____ Date _____

HFD-590/Micro TL _____ Signature _____ Date _____

CC:

HFD-590/Original IND

HFD-590/Division File

HFD-590/MO

HFD-590/Pharm

HFD-590/Chem

HFD-590/Review Micro

HFD-590/CSO/MillerK

Cryptaz
Romark Laboratories

I. REFERENCES:

- ¹ Hoffman PS. (2002). Studies of the mechanism of action of nitazoxanide against anaerobic protozoa and bacteria. Report RM01-0401.
- ² Tzipori S. (2002). Determination of drug activity in an *in vitro* model of cryptosporidiosis. Report ROM-022.
- ³ Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori S. (1998). Efficacy of nitazoxanide against *Cryptosporidium parvum* in cell culture and in animal models. *Antimicrob Agents Chemother.* **42**:1959-1965.
- ⁴ Giacometti A, Burzacchini F, Cirioni O, Barchiesi F, Dini M, Scalise G. (1999). Efficacy of treatment with paramomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. *Eur J Clin Microbiol Infect Dis.* **18**:885-889.
- ⁵ Giacometti A, Cirioni O, Barchiesi F, Ancarani F, Scalise G. (2000). Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against *Cryptosporidium parvum* in cell culture. *J Anti Chem.* **45**:453-456.
- ⁶ Favennec L. (2002). Efficacy of nitazoxanide, tizoxanide, and tizoxanide glucuronide against *Cryptosporidium parvum* in HCT-8 cell cultures. Report RM01-0005.
- ⁷ Gargala , Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ. (2000). Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against *Cryptosporidium parvum* development in sporozoite-infected HCT-8 enterocytic cells. *J Anti Chem.* **46**: 57-60.
- ⁸ Soliman MS. (1997). Study of the parasitical activity of nitazoxanide against *Cryptosporidium parvum*. Report ROM-019.
- ⁹ Blagburn BL, Drain KL, Land TM, Kinard RG, Moore PH, Lindsay DS, Patrick DA, Boykin DW, Tidwell RR. (1998). Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against *Cryptosporidium parvum* infections in a neonatal mouse model. *Antimicrob Agents Chemother.* **42**:2977-2882.
- ¹⁰ Tzipori S. (2002). Determination of drug activity in a murine model of acute cryptosporidiosis. Report ROM-005.
- ¹¹ Brasseur P, Li X. (1999). Evaluation of the anticryptosporidial activity of nitazoxanide using an immunosuppressed rat model. Report RM-99.208 (amended 2002).
- ¹² Tzipori S. (2002). Determination of drug activity in the diarrhea piglet model of acute cryptosporidiosis. Report ROM-021.
- ¹³ Current WL, Garcia LS. (1991). Cryptosporidiosis. *Clin. Micro Rev.* **4**:325-358.

-
- 14 Ma P.(1986). *Cryptosporidium*-biology and diagnosis. Adv Exp Med Biol. 202: 135-152.
 - 15 Warhurst DC. (2000). Activity of nitazoxanide and its metabolites *in vitro* against *Giardia intestinalis* and *Entamoeba histolytica*. Report RM-00.201.
 - 16 Adagu SI, Nolder D, Warhurst DC, Rossignol JF. (2002). *In vitro* activity of nitazoxanide and related compounds against isolates of *Giardia intestinalis*, *Entamoeba histolytica* and *Trichomonas vaginalis*. J. Antimicrob Chemother. 49:103-111.
 - 17 Favennec L. (1999). Efficacy of nitazoxanide, tizoxanide, metronidazole and albendazole against *Giardia duodenalis* in Caco-2 cell culture. Report RM-99.204.
 - 18 Favennec L. (1999). Efficacy study of nitazoxanide against *Giardia duodenale* in experimentally infected neonatal mice. Report RM-99.205.
 - 19 Hoffman PS. (1999). Study of the mechanism of action of nitazoxanide using *Helicobacter pylori* and *Escherichia coli* test systems. Report RM-99.202.
 - 20 Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, Hoffman PS. (2002). Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in *Helicobacter pylori*. Antimicrob Agents Chemother. 46:2116-2123.
 - 21 Hoffman PS. (1999). Study of the reduction of metronidazole and nitazoxanide by the *Helicobacter pylori* nitroreductase (*rdxA*) and the corresponding effect on mutation frequency and DNA damage. Report RM-99.201
 - 22 Yamamota Y, Hakki A, Friedman H, Okubo S, Shimamura T, Hoffman PS, Rossignol JF. (1999). Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-helicobacter pylori agent with anti-vacuolating toxin activity. Chemotherapy 45: 303-312.
 - 23 Rossignol JF. (1996). *In vitro* testing of nitazoxanide and tizoxanide against metronidazole-resistant and metronidazole-sensitive strains of *Trichomonas vaginalis*. Report RM-96.201
 - 24 Cavier R, Rossignol JF. (1998). *In vitro* and *in vivo* efficacy of nitazoxanide against *Trichomonas vaginalis*. Report RM-98.202
 - 25 Cavier R. (1978). Efficacy of PH.5776 against *Trichomonas vaginalis*, *Entamoeba histolytica*, *Syphacia obvelata*, *Hymenolepis nana* and *Biophalaria glabarata*. Report RM-78.201.
 - 26 Didier ES, Maddry JA, Kwong CD, Green LC, Snowden KF, Shaddock JA. (1998). Screening of compounds for antimicrosporidial activity *in vitro*. Folia Parasitol. 45:129-139.
 - 27 Malone JB. (1995). *In vitro* efficacy of nitazoxanide and diacetyl-nitazoxanide against *Fasciola hepatica*. Report RM-95.201.

Cryptaz

Romark Laboratories

- ²⁸ Soliman MS. (1998). Study of the antihelminthic activity of nitazoxanide against the immature and mature stages of *Fasciola gigantica* in experimentally infected rabbits. Report RM-99.206.
- ²⁹ Euzeby J, L'Etolle M. (1978). Efficacy study of nitazoxanide against intestinal nematodes and cestodes in dogs. Report ROM-007.
- ³⁰ Euzeby J, Prom Tep S, Rossignol JF. (1980). Study of the antihelminthic activity of nitazoxanide in dogs, cats and sheeps. *Revue Med Vet* **131**:687-696.
- ³¹ Dubreuil L. (1996). *In vitro* evaluation of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Report RM-96.202
- ³² Dubreuil L, Houcke I, Mouton Y, Rossignol JF. (1996). *In vitro* evaluations of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. *Antimicrob Agents Chemother.* **40**: 2266-2270.
- ³³ Megraud F, Occhialini A, Rossignol JF. (1998). Nitazoxanide, a potential drug for eradication of *Helicobacter pylori* with no cross-resistance to metronidazole. *Antimicrob Agents Chemother.* **42**:2836-2840. (Report RM-98.204).
- ³⁴ Rolfe RD. (1998). Studies of the activity of nitazoxanide, vancomycin and metronidazole against *Clostridium difficile*. Report RM-98.207.
- ³⁵ McVay CS, Rolfe RD. (2000). *In vitro* and *in vivo* activities of nitazoxanide against *Clostridium difficile*. *Antimicrob Agents Chemother.* **44**: 2254-2258.
- ³⁶ Gargala G. (2002). Investigation of the influence of nitazoxanide on iNOS, IL-8 and IP-10 mRNA levels and IL-8 and nitric oxide production in unstimulated or cytokine-stimulated HCT-8 cell cultures. Report RM 01-0402.

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Kalavati Suvarna
11/19/02 04:42:43 PM
MICROBIOLOGIST

Shukal Bala
11/20/02 07:26:08 AM
MICROBIOLOGIST